{ "disease": "cervical-cancer", "label": "Cervical cancer", "url": "https://usebiotransfer.org/disease/cervical-cancer/", "built": "2026-09-12", "facts_hash": { "answers": "7365ef047177", "targets": "1262753e64ec" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-12", "trials": "2026-09-12" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "PIK3CA", "ensembl": "ENSG00000121879", "n_drug_entries": 32, "n_distinct_drugs": 31, "drugs": { "ALPELISIB": "APPROVAL", "APITOLISIB": "PHASE_2", "AZD-6482": "UNKNOWN", "BAY-1082439": "PHASE_1", "BGT-226": "PHASE_1_2", "BUPARLISIB": "PHASE_3", "COPANLISIB": "APPROVAL", "DACTOLISIB": "PHASE_3", "DS-7423": "PHASE_1", "FIMEPINOSTAT": "PHASE_2", "GEDATOLISIB": "PHASE_3", "GSK-1059615": "PHASE_1", "INAVOLISIB": "APPROVAL", "IZORLISIB": "PHASE_1_2", "OMIPALISIB": "PHASE_1", "PANULISIB": "PHASE_1", "PAXALISIB": "PHASE_2_3", "PF-04691502": "PHASE_2", "PICTILISIB": "PHASE_2", "PILARALISIB": "PHASE_2", "PKI-179": "PHASE_1", "RECILISIB": "PHASE_1", "SAMOTOLISIB": "PHASE_2", "SERABELISIB": "PHASE_2", "SF-1126": "PHASE_2", "SONOLISIB": "PHASE_2", "TASELISIB": "PHASE_3", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1", "WX-037": "PHASE_1", "ZSTK-474": "PHASE_1" }, "approved": [ "ALPELISIB", "COPANLISIB", "INAVOLISIB" ], "n_approved": 3, "approved_for": { "ALPELISIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "COPANLISIB": [ "follicular lymphoma", "non-Hodgkin lymphoma", "neoplasm of mature B-cells" ], "INAVOLISIB": [ "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "CD274", "ensembl": "ENSG00000120217", "n_drug_entries": 13, "n_distinct_drugs": 13, "drugs": { "ADEBRELIMAB": "PHASE_3", "ATEZOLIZUMAB": "APPROVAL", "AVELUMAB": "APPROVAL", "BINTRAFUSP ALFA": "PHASE_3", "COSIBELIMAB": "APPROVAL", "DANBURSTOTUG": "PHASE_2", "DURVALUMAB": "APPROVAL", "ENVAFOLIMAB": "PHASE_3", "ERFONRILIMAB": "PHASE_3", "INCB-086550": "PHASE_2", "PACMILIMAB": "PHASE_2", "SOCAZOLIMAB": "PHASE_3", "SUGEMALIMAB": "APPROVAL" }, "approved": [ "ATEZOLIZUMAB", "AVELUMAB", "COSIBELIMAB", "DURVALUMAB", "SUGEMALIMAB" ], "n_approved": 5, "approved_for": { "ATEZOLIZUMAB": [ "urothelial carcinoma", "non-small cell lung carcinoma", "breast cancer", "small cell lung carcinoma", "breast neoplasm", "transitional cell carcinoma" ], "AVELUMAB": [ "Merkel cell skin cancer", "urothelial carcinoma", "neuroendocrine neoplasm" ], "COSIBELIMAB": [ "head and neck squamous cell carcinoma" ], "DURVALUMAB": [ "non-small cell lung carcinoma", "small cell lung carcinoma", "urothelial carcinoma", "hepatocellular carcinoma" ], "SUGEMALIMAB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "PDCD1", "ensembl": "ENSG00000188389", "n_drug_entries": 26, "n_distinct_drugs": 26, "drugs": { "APL-501": "PHASE_2", "BALSTILIMAB": "PHASE_3", "BUDIGALIMAB": "PHASE_2_3", "CADONILIMAB": "PHASE_3", "CAMRELIZUMAB": "PHASE_3", "CEMIPLIMAB": "APPROVAL", "CETRELIMAB": "PHASE_3", "CS-1003": "PHASE_3", "DOSTARLIMAB": "APPROVAL", "FINOTONLIMAB": "PHASE_3", "LOMVASTOMIG": "PHASE_2", "NIVOLUMAB": "APPROVAL", "PEMBROLIZUMAB": "APPROVAL", "PENPULIMAB": "PHASE_3", "PIDILIZUMAB": "PHASE_2", "PIMIVALIMAB": "PHASE_2", "PUCOTENLIMAB": "PHASE_3", "RETIFANLIMAB": "APPROVAL", "SASANLIMAB": "PHASE_3", "SERPLULIMAB": "APPROVAL", "SINTILIMAB": "APPROVAL", "SPARTALIZUMAB": "PHASE_3", "TEBOTELIMAB": "PHASE_2_3", "TISLELIZUMAB": "APPROVAL", "TORIPALIMAB": "APPROVAL", "ZIMBERELIMAB": "PHASE_3" }, "approved": [ "CEMIPLIMAB", "DOSTARLIMAB", "NIVOLUMAB", "PEMBROLIZUMAB", "RETIFANLIMAB", "SERPLULIMAB", "SINTILIMAB", "TISLELIZUMAB", "TORIPALIMAB" ], "n_approved": 9, "approved_for": { "CEMIPLIMAB": [ "squamous cell carcinoma", "basal cell carcinoma", "cutaneous squamous cell carcinoma", "cervical cancer" ], "DOSTARLIMAB": [ "endometrial cancer", "endometrial neoplasm" ], "NIVOLUMAB": [ "head and neck cancer", "pleural mesothelioma", "gastric cancer", "melanoma", "non-small cell lung carcinoma", "renal cell carcinoma", "transitional cell carcinoma", "colorectal neoplasm", "Hodgkins lymphoma", "mesothelioma", "head and neck squamous cell carcinoma", "classic Hodgkin lymphoma", "metastatic melanoma" ], "PEMBROLIZUMAB": [ "melanoma", "metastatic melanoma", "endometrium neoplasm", "head and neck squamous cell carcinoma", "transitional cell carcinoma", "renal cell carcinoma", "Hodgkins lymphoma", "non-small cell lung carcinoma" ], "RETIFANLIMAB": [ "neuroendocrine carcinoma", "Merkel cell skin cancer", "squamous cell carcinoma" ], "SERPLULIMAB": [ "esophageal squamous cell carcinoma", "non-small cell lung carcinoma", "small cell lung carcinoma" ], "SINTILIMAB": [ "Hodgkins lymphoma" ], "TISLELIZUMAB": [ "esophageal cancer", "Hodgkins lymphoma", "non-small cell lung carcinoma", "adenocarcinoma", "esophageal squamous cell carcinoma", "gastric neoplasm" ], "TORIPALIMAB": [ "melanoma", "nasopharyngeal carcinoma", "urothelial carcinoma", "esophageal squamous cell carcinoma", "Niemann-Pick disease type B" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "ERBB2", "ensembl": "ENSG00000141736", "n_drug_entries": 48, "n_distinct_drugs": 45, "drugs": { "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "ANVATABART OPADOTIN": "PHASE_2_3", "AV-412": "PHASE_1", "BMS-690514": "PHASE_2", "CANERTINIB": "PHASE_2", "CP-724714": "PHASE_2", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DISITAMAB VEDOTIN": "PHASE_3", "ERTUMAXOMAB": "PHASE_2", "GANCOTAMAB": "PHASE_2_3", "HEMAY-022": "PHASE_3", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "KN-026": "PHASE_3", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "MARGETUXIMAB": "APPROVAL", "MASOPROCOL": "APPROVAL", "MM-111": "PHASE_2", "MUBRITINIB": "PHASE_1", "NERATINIB": "APPROVAL", "PERTUZUMAB": "APPROVAL", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "TRASTUZUMAB": "APPROVAL", "TRASTUZUMAB BOTIDOTIN": "PHASE_3", "TRASTUZUMAB DERUXTECAN": "APPROVAL", "TRASTUZUMAB DUOCARMAZINE": "APPROVAL", "TRASTUZUMAB EMTANSINE": "APPROVAL", "TUCATINIB": "APPROVAL", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZANIDATAMAB": "APPROVAL", "ZENOCUTUZUMAB": "APPROVAL" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "DACOMITINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "MARGETUXIMAB", "MASOPROCOL", "NERATINIB", "PERTUZUMAB", "TRASTUZUMAB", "TRASTUZUMAB DERUXTECAN", "TRASTUZUMAB DUOCARMAZINE", "TRASTUZUMAB EMTANSINE", "TUCATINIB", "VANDETANIB", "ZANIDATAMAB", "ZENOCUTUZUMAB" ], "n_approved": 17, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "MARGETUXIMAB": [ "HER2 positive breast carcinoma", "breast cancer" ], "MASOPROCOL": [ "prostate cancer" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "PERTUZUMAB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB": [ "breast cancer", "breast carcinoma", "gastric cancer", "gastric neoplasm", "breast neoplasm" ], "TRASTUZUMAB DERUXTECAN": [ "breast cancer", "HER2 positive breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB DUOCARMAZINE": [], "TRASTUZUMAB EMTANSINE": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TUCATINIB": [ "HER2 positive breast carcinoma", "metastasis", "breast neoplasm", "breast cancer", "colorectal carcinoma", "breast carcinoma" ], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ], "ZANIDATAMAB": [ "biliary tract neoplasm" ], "ZENOCUTUZUMAB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "KRAS", "ensembl": "ENSG00000133703", "n_drug_entries": 3, "n_distinct_drugs": 3, "drugs": { "ADAGRASIB": "APPROVAL", "SALIRASIB": "PHASE_2", "SOTORASIB": "APPROVAL" }, "approved": [ "ADAGRASIB", "SOTORASIB" ], "n_approved": 2, "approved_for": { "ADAGRASIB": [ "non-small cell lung carcinoma" ], "SOTORASIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "PTEN", "ensembl": "ENSG00000171862", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "FBXW7", "ensembl": "ENSG00000109670", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "EGFR", "ensembl": "ENSG00000146648", "n_drug_entries": 82, "n_distinct_drugs": 74, "drugs": { "ABIVERTINIB": "PHASE_3", "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "AMIVANTAMAB": "APPROVAL", "AUMOLERTINIB": "APPROVAL", "AV-412": "PHASE_1", "AZD-3759": "PHASE_2_3", "AZD-4769": "PHASE_1", "BAFISONTAMAB": "PHASE_2", "BMS-690514": "PHASE_2", "BRIGATINIB": "APPROVAL", "CANERTINIB": "PHASE_2", "CEP-32496": "PHASE_1_2", "CETUXIMAB": "APPROVAL", "CETUXIMAB SAROTALOCAN": "APPROVAL", "CLN-081": "PHASE_3", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DEPATUXIZUMAB": "PHASE_2", "DEPATUXIZUMAB MAFODOTIN": "PHASE_3", "DULIGOTUZUMAB": "PHASE_2", "EPITINIB": "PHASE_1", "ERLOTINIB": "APPROVAL", "FALNIDAMOL": "PHASE_1", "FIRMONERTINIB": "PHASE_3", "FUTUXIMAB": "PHASE_3", "GC1118": "PHASE_2", "GEFITINIB": "APPROVAL", "ICOTINIB": "APPROVAL", "IMGATUZUMAB": "PHASE_2", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "LAZERTINIB": "APPROVAL", "LOSATUXIZUMAB VEDOTIN": "PHASE_1", "MAB-425": "UNKNOWN", "MATUZUMAB": "PHASE_2", "MAVELERTINIB": "PHASE_1_2", "MDX-447": "PHASE_1", "MOBOCERTINIB": "APPROVAL", "MODOTUXIMAB": "PHASE_2", "NAQUOTINIB": "PHASE_3", "NAZARTINIB": "PHASE_3", "NECITUMUMAB": "APPROVAL", "NERATINIB": "APPROVAL", "NIMOTUZUMAB": "APPROVAL", "OLMUTINIB": "APPROVAL", "OSIMERTINIB": "APPROVAL", "PANITUMUMAB": "APPROVAL", "PELITINIB": "PHASE_2", "PF-06459988": "PHASE_2", "PIMURUTAMAB": "PHASE_2_3", "PKI-166": "PHASE_2", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "RINDOPEPIMUT": "PHASE_3", "ROCILETINIB": "APPROVAL", "RUSERONTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "SIMOTINIB": "PHASE_1", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "THELIATINIB": "PHASE_1", "TOMUZOTUXIMAB": "PHASE_2", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZALUTUMUMAB": "PHASE_3" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "AMIVANTAMAB", "AUMOLERTINIB", "BRIGATINIB", "CETUXIMAB", "CETUXIMAB SAROTALOCAN", "DACOMITINIB", "ERLOTINIB", "GEFITINIB", "ICOTINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "LAZERTINIB", "MOBOCERTINIB", "NECITUMUMAB", "NERATINIB", "NIMOTUZUMAB", "OLMUTINIB", "OSIMERTINIB", "PANITUMUMAB", "ROCILETINIB", "VANDETANIB" ], "n_approved": 23, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "AMIVANTAMAB": [ "non-small cell lung carcinoma" ], "AUMOLERTINIB": [ "non-small cell lung carcinoma" ], "BRIGATINIB": [ "non-small cell lung carcinoma", "anaplastic large cell lymphoma" ], "CETUXIMAB": [ "malignant tumor of neck", "squamous cell carcinoma", "colorectal adenocarcinoma", "colorectal carcinoma", "colorectal cancer", "head and neck neoplasm", "colorectal neoplasm" ], "CETUXIMAB SAROTALOCAN": [ "head and neck cancer" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "ERLOTINIB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ], "GEFITINIB": [ "non-small cell lung carcinoma", "head and neck squamous cell carcinoma" ], "ICOTINIB": [], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "LAZERTINIB": [ "non-small cell lung carcinoma" ], "MOBOCERTINIB": [ "non-small cell lung carcinoma" ], "NECITUMUMAB": [ "non-small cell lung carcinoma", "colorectal cancer", "non-small cell squamous lung carcinoma" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "NIMOTUZUMAB": [ "head and neck cancer" ], "OLMUTINIB": [], "OSIMERTINIB": [ "non-small cell lung carcinoma" ], "PANITUMUMAB": [ "colorectal cancer", "colorectal adenocarcinoma", "colorectal neoplasm" ], "ROCILETINIB": [], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "TACSTD2", "ensembl": "ENSG00000184292", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "DATOPOTAMAB DERUXTECAN": "APPROVAL", "SACITUZUMAB GOVITECAN": "APPROVAL" }, "approved": [ "DATOPOTAMAB DERUXTECAN", "SACITUZUMAB GOVITECAN" ], "n_approved": 2, "approved_for": { "DATOPOTAMAB DERUXTECAN": [ "breast cancer", "breast neoplasm", "non-small cell lung carcinoma" ], "SACITUZUMAB GOVITECAN": [ "breast cancer", "urothelial carcinoma", "triple-negative breast carcinoma", "breast neoplasm" ] }, "tractability": [ { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "TERT", "ensembl": "ENSG00000164362", "n_drug_entries": 2, "n_distinct_drugs": 1, "drugs": { "IMETELSTAT": "APPROVAL" }, "approved": [ "IMETELSTAT" ], "n_approved": 1, "approved_for": { "IMETELSTAT": [ "anemia", "myelodysplastic syndrome" ] }, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "CDKN2A", "ensembl": "ENSG00000147889", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [] } ], "trials": { "by_antigen": { "PD-1": { "n": 526, "n_observational": 32, "n_active": 230, "n_withdrawn": 27, "trials": [ { "nct": "NCT03406247", "title": "Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03526835", "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04114136", "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04370587", "title": "A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2025-10-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04375384", "title": "Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04429542", "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-08-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04712851", "title": "Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia", "status": "RECRUITING", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722523", "title": "A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04787042", "title": "Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067", "status": "RECRUITING", "last_update": "2024-11-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04807673", "title": "Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)", "status": "RECRUITING", "last_update": "2022-06-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04875611", "title": "Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment", "status": "RECRUITING", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895709", "title": "A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04954599", "title": "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988074", "title": "Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05025813", "title": "Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2022-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05047094", "title": "Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076760", "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05136196", "title": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05176483", "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05208762", "title": "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05286619", "title": "A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)", "status": "RECRUITING", "last_update": "2024-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317000", "title": "5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342792", "title": "Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2022-04-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05357846", "title": "PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05358548", "title": "ATATcH Alternating Treatment Plans for Advanced Cancer", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05483400", "title": "Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors", "status": "RECRUITING", "last_update": "2025-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05669430", "title": "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2025-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05784688", "title": "Study of TU2218 in Combination With KEYTRUDA\u00ae(Pembrolizumab) in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05799144", "title": "pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS\u22651, hrHPV+ Oropharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05815927", "title": "Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05838729", "title": "Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer", "status": "RECRUITING", "last_update": "2025-09-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05859074", "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05977907", "title": "Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06019130", "title": "Nivolumab in Children and Adults With Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022029", "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022861", "title": "A Study to Compare the Efficacy and Safety of LY01015 and Opdivo\u00ae Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06029270", "title": "Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06064097", "title": "A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06081673", "title": "Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC", "status": "RECRUITING", "last_update": "2023-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06086457", "title": "PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06102395", "title": "Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC", "status": "RECRUITING", "last_update": "2023-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06122493", "title": "Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123884", "title": "BAT1308 Combined with Platinum-Based Chemotherapy\u00b1 Bevacizumab for PDL1-Positive (CPS \u22651) Cervical Cancer", "status": "RECRUITING", "last_update": "2025-02-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06137378", "title": "European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]", "status": "RECRUITING", "last_update": "2024-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161545", "title": "Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06170710", "title": "Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC", "status": "RECRUITING", "last_update": "2023-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06190782", "title": "Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor", "status": "RECRUITING", "last_update": "2024-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265285", "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06266338", "title": "Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06270706", "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06289062", "title": "Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06323239", "title": "SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06383780", "title": "Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06448026", "title": "Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06457503", "title": "A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06494995", "title": "AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy", "status": "RECRUITING", "last_update": "2025-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532799", "title": "TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06589804", "title": "Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06636734", "title": "Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06638931", "title": "Agnostic Therapy in Rare Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06640283", "title": "Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06699212", "title": "A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases", "status": "RECRUITING", "last_update": "2025-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769698", "title": "A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773507", "title": "Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06787911", "title": "Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer", "status": "RECRUITING", "last_update": "2025-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06788990", "title": "FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06802835", "title": "EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06823479", "title": "Towards Cure Via Only Ultra-short ICB in CSCC", "status": "RECRUITING", "last_update": "2025-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06868433", "title": "TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06902376", "title": "XL092 and Cemiplimab in BRAF WT Thyroid Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06907602", "title": "Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912087", "title": "Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06923761", "title": "EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)", "status": "RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06980038", "title": "Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07040072", "title": "Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07061977", "title": "Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07071103", "title": "Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07152678", "title": "Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172256", "title": "CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07179315", "title": "A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195734", "title": "Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07205731", "title": "Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07213934", "title": "Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07223424", "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07254585", "title": "SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07277764", "title": "Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07290010", "title": "The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07317609", "title": "Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332247", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339488", "title": "Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07343596", "title": "Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07403136", "title": "Becotatug Vedotin \u00b1 Anti-PD-1 in Pretreated Advanced ESCC", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405151", "title": "A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07423078", "title": "Window of Opportunity in Preserving Laryngeal Function Trial", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07455019", "title": "A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07460765", "title": "Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07472153", "title": "PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07485296", "title": "Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07501650", "title": "Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07559045", "title": "Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07629817", "title": "Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07645625", "title": "Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer", "status": "RECRUITING", "last_update": "2026-06-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653503", "title": "Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07781358", "title": "Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01818323", "title": "Phase I Trial: T4 Immunotherapy of Head and Neck Cancer", "status": "UNKNOWN", "last_update": "2024-10-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02105636", "title": "Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)", "status": "COMPLETED", "last_update": "2022-10-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02124850", "title": "A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab", "status": "TERMINATED", "last_update": "2019-10-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02335918", "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2019-12-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02376699", "title": "Safety Study of SEA-CD40 in Cancer Patients", "status": "TERMINATED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423863", "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol\u00ae", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02475213", "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer", "status": "COMPLETED", "last_update": "2025-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02526017", "title": "Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02538510", "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2024-11-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02559687", "title": "Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)", "status": "COMPLETED", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02569242", "title": "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02575404", "title": "GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients", "status": "COMPLETED", "last_update": "2023-06-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02609503", "title": "Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02626000", "title": "Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)", "status": "COMPLETED", "last_update": "2021-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02636036", "title": "Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors", "status": "COMPLETED", "last_update": "2021-11-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02637531", "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549", "status": "UNKNOWN", "last_update": "2022-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02641093", "title": "Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02684253", "title": "Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "COMPLETED", "last_update": "2022-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02707588", "title": "Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC", "status": "COMPLETED", "last_update": "2023-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02735239", "title": "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer", "status": "COMPLETED", "last_update": "2024-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02741570", "title": "Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02757391", "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors", "status": "TERMINATED", "last_update": "2020-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02764593", "title": "Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2022-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02775812", "title": "Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2022-06-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02799095", "title": "A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors", "status": "COMPLETED", "last_update": "2025-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02823574", "title": "Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2023-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02829931", "title": "Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas", "status": "COMPLETED", "last_update": "2023-01-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02830594", "title": "Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2024-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834247", "title": "A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02841748", "title": "A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02842125", "title": "Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2020-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02882282", "title": "Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia", "status": "COMPLETED", "last_update": "2025-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02915432", "title": "The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC", "status": "UNKNOWN", "last_update": "2021-12-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02946671", "title": "Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients", "status": "COMPLETED", "last_update": "2020-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2019-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02955290", "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02973997", "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)", "status": "COMPLETED", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03003637", "title": "ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma", "status": "COMPLETED", "last_update": "2023-10-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03006887", "title": "Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors", "status": "COMPLETED", "last_update": "2021-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03012581", "title": "Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03021993", "title": "Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer", "status": "COMPLETED", "last_update": "2025-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03040999", "title": "Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)", "status": "COMPLETED", "last_update": "2026-02-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03044613", "title": "Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03058289", "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6", "status": "COMPLETED", "last_update": "2025-02-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097939", "title": "Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03099382", "title": "Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2024-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03107182", "title": "Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer", "status": "COMPLETED", "last_update": "2025-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03121716", "title": "A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects", "status": "COMPLETED", "last_update": "2022-07-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03129061", "title": "Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "status": "COMPLETED", "last_update": "2022-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03132038", "title": "Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162731", "title": "Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03189719", "title": "First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)", "status": "COMPLETED", "last_update": "2024-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03196232", "title": "Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03198130", "title": "An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)", "status": "COMPLETED", "last_update": "2020-03-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03229278", "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma", "status": "COMPLETED", "last_update": "2023-12-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03236935", "title": "Phase Ib of L-NMMA and Pembrolizumab", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03238638", "title": "A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy", "status": "WITHDRAWN", "last_update": "2018-01-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03246958", "title": "Nivolumab Plus Ipilimumab in Thyroid Cancer", "status": "COMPLETED", "last_update": "2025-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03247712", "title": "Neoadjuvant Immunoradiotherapy in Head & Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03257267", "title": "Study of Cemiplimab in Adults With Cervical Cancer", "status": "COMPLETED", "last_update": "2025-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03267498", "title": "Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2026-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03278626", "title": "Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2022-03-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03291002", "title": "Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC", "status": "UNKNOWN", "last_update": "2021-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03298893", "title": "Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)", "status": "COMPLETED", "last_update": "2025-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03313804", "title": "Priming Immunotherapy in Advanced Disease With Radiation", "status": "COMPLETED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03317327", "title": "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors", "status": "COMPLETED", "last_update": "2025-06-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03342352", "title": "Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)", "status": "WITHDRAWN", "last_update": "2019-12-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03342911", "title": "Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03342937", "title": "KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer", "status": "COMPLETED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03347123", "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)", "status": "TERMINATED", "last_update": "2022-02-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03347838", "title": "Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03349710", "title": "Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-08-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03355560", "title": "Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy", "status": "COMPLETED", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03360890", "title": "Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03370276", "title": "Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386357", "title": "Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "TERMINATED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386838", "title": "An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck", "status": "WITHDRAWN", "last_update": "2019-04-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03390738", "title": "Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy", "status": "WITHDRAWN", "last_update": "2021-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03402737", "title": "SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N", "status": "TERMINATED", "last_update": "2021-02-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03412058", "title": "Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03416244", "title": "A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2022-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03427827", "title": "PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03435640", "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies", "status": "TERMINATED", "last_update": "2023-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03444376", "title": "The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer", "status": "COMPLETED", "last_update": "2025-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03463161", "title": "Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy", "status": "TERMINATED", "last_update": "2020-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03469557", "title": "BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474497", "title": "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03508570", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis", "status": "COMPLETED", "last_update": "2025-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03511391", "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03521570", "title": "Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544736", "title": "Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03565445", "title": "A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03565783", "title": "Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03575234", "title": "Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2019-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03575598", "title": "Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study", "status": "COMPLETED", "last_update": "2023-07-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03576417", "title": "A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03578406", "title": "HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer", "status": "COMPLETED", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03592407", "title": "Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer", "status": "WITHDRAWN", "last_update": "2022-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03620123", "title": "A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2022-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03621982", "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-06-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03625323", "title": "Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC", "status": "COMPLETED", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03629756", "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-05-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633110", "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine", "status": "COMPLETED", "last_update": "2022-04-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03646461", "title": "Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC", "status": "TERMINATED", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03652233", "title": "Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "WITHDRAWN", "last_update": "2019-06-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03655444", "title": "Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy", "status": "TERMINATED", "last_update": "2020-12-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03669718", "title": "A Randomized Phase 2 Study of Cemiplimab \u00b1 ISA101b in HPV16-Positive OPC", "status": "UNKNOWN", "last_update": "2023-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03674567", "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03684785", "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2022-04-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03692325", "title": "Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03693014", "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03707509", "title": "Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708328", "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03715946", "title": "Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer", "status": "COMPLETED", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03721757", "title": "CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer", "status": "COMPLETED", "last_update": "2025-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03727061", "title": "Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer", "status": "TERMINATED", "last_update": "2025-03-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735290", "title": "A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer", "status": "TERMINATED", "last_update": "2022-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735628", "title": "An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03749460", "title": "Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers", "status": "COMPLETED", "last_update": "2023-12-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03758729", "title": "Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.", "status": "WITHDRAWN", "last_update": "2021-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03758781", "title": "IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03764553", "title": "Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03765918", "title": "Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766178", "title": "Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03769467", "title": "Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)", "status": "TERMINATED", "last_update": "2024-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03789097", "title": "Vaccination With Flt3L, Radiation, and Poly-ICLC", "status": "COMPLETED", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03792347", "title": "Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus", "status": "COMPLETED", "last_update": "2023-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03799003", "title": "A Study of ASP1951 in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03799445", "title": "Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811015", "title": "Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811652", "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2019-12-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813836", "title": "Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03816553", "title": "SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer", "status": "COMPLETED", "last_update": "2023-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03823131", "title": "Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat", "status": "TERMINATED", "last_update": "2023-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03827837", "title": "Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors", "status": "UNKNOWN", "last_update": "2022-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829436", "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers", "status": "COMPLETED", "last_update": "2023-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829722", "title": "Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03843515", "title": "Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction", "status": "UNKNOWN", "last_update": "2021-10-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854032", "title": "Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878979", "title": "Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN", "status": "COMPLETED", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03881111", "title": "First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study", "status": "WITHDRAWN", "last_update": "2020-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03894891", "title": "Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer", "status": "COMPLETED", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03906526", "title": "A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer", "status": "TERMINATED", "last_update": "2023-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03914300", "title": "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03914443", "title": "A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2025-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03916627", "title": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03925090", "title": "Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03933449", "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03938337", "title": "Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer", "status": "TERMINATED", "last_update": "2021-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946969", "title": "Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03952585", "title": "De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03972722", "title": "Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer", "status": "UNKNOWN", "last_update": "2019-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03984357", "title": "Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03987815", "title": "Neoadjuvant Nivolumab for Operable Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03993353", "title": "Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04005170", "title": "Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007744", "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04030455", "title": "Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04032704", "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042116", "title": "A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor", "status": "SUSPENDED", "last_update": "2022-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044859", "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04058145", "title": "AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2020-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04061980", "title": "Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04074967", "title": "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04080804", "title": "Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04083599", "title": "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04139057", "title": "EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC", "status": "COMPLETED", "last_update": "2026-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04143984", "title": "Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04146181", "title": "Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2019-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04150575", "title": "A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy", "status": "UNKNOWN", "last_update": "2022-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04150900", "title": "1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152018", "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.", "status": "TERMINATED", "last_update": "2025-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04154943", "title": "Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04180371", "title": "Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04187872", "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis", "status": "TERMINATED", "last_update": "2023-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04195373", "title": "A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract", "status": "WITHDRAWN", "last_update": "2020-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04199104", "title": "A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)", "status": "COMPLETED", "last_update": "2026-05-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04203719", "title": "A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer", "status": "UNKNOWN", "last_update": "2020-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209660", "title": "Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04222972", "title": "A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-03-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229459", "title": "Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230954", "title": "Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer", "status": "TERMINATED", "last_update": "2022-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04238624", "title": "Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04256213", "title": "COL Immunotherapy Before Radiochimio + Ipilimumab", "status": "COMPLETED", "last_update": "2024-12-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260126", "title": "Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC", "status": "COMPLETED", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04266730", "title": "Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab", "status": "SUSPENDED", "last_update": "2026-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282109", "title": "Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)", "status": "COMPLETED", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04291105", "title": "Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305795", "title": "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04326257", "title": "Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy", "status": "COMPLETED", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04349267", "title": "Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04357873", "title": "Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations", "status": "COMPLETED", "last_update": "2025-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04369937", "title": "HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for \"Intermediate Risk\" HPV-16-associated Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389177", "title": "Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398056", "title": "Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398524", "title": "A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC", "status": "UNKNOWN", "last_update": "2024-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04428151", "title": "Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432857", "title": "AN0025 and Pembrolizumab Combination in Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04452214", "title": "A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors", "status": "COMPLETED", "last_update": "2023-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04454489", "title": "Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition", "status": "COMPLETED", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458909", "title": "Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer", "status": "TERMINATED", "last_update": "2025-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "status": "UNKNOWN", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04465487", "title": "Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies", "status": "TERMINATED", "last_update": "2025-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04503967", "title": "Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514484", "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04517214", "title": "Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04523883", "title": "Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)", "status": "UNKNOWN", "last_update": "2021-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04541108", "title": "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04555837", "title": "Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2025-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04557020", "title": "Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC", "status": "UNKNOWN", "last_update": "2024-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04570839", "title": "COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.", "status": "COMPLETED", "last_update": "2024-07-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603248", "title": "A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-06-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04609566", "title": "Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624113", "title": "Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma", "status": "TERMINATED", "last_update": "2024-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04625543", "title": "Neoadjuvant Immunotherapy to ESCC", "status": "WITHDRAWN", "last_update": "2022-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04641728", "title": "Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer", "status": "UNKNOWN", "last_update": "2022-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04641871", "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2024-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04643379", "title": "Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04646005", "title": "Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy", "status": "COMPLETED", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04651127", "title": "Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer", "status": "TERMINATED", "last_update": "2026-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04652076", "title": "GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659369", "title": "Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC", "status": "TERMINATED", "last_update": "2024-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "status": "UNKNOWN", "last_update": "2024-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04670679", "title": "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04682431", "title": "A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704154", "title": "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors", "status": "COMPLETED", "last_update": "2025-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04736810", "title": "A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04757363", "title": "A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04767295", "title": "A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)", "status": "UNKNOWN", "last_update": "2021-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04769076", "title": "The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04785820", "title": "A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04795713", "title": "Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04806945", "title": "A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer", "status": "WITHDRAWN", "last_update": "2022-05-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04811027", "title": "Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04825990", "title": "Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830592", "title": "A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2025-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04831320", "title": "Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04831450", "title": "Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "WITHDRAWN", "last_update": "2022-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04848116", "title": "Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862455", "title": "NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862650", "title": "Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04870177", "title": "Study of AK112 in the Treatment of Advanced Gynecological Tumors", "status": "COMPLETED", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04872582", "title": "Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study", "status": "UNKNOWN", "last_update": "2023-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04879849", "title": "A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers", "status": "COMPLETED", "last_update": "2025-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04891718", "title": "CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia", "status": "WITHDRAWN", "last_update": "2022-07-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892043", "title": "Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895735", "title": "MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04913337", "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies", "status": "UNKNOWN", "last_update": "2024-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04918628", "title": "Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04921995", "title": "Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925284", "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)", "status": "COMPLETED", "last_update": "2025-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04936841", "title": "Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04943445", "title": "Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers", "status": "COMPLETED", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04943627", "title": "Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)", "status": "WITHDRAWN", "last_update": "2022-10-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04943900", "title": "A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors", "status": "COMPLETED", "last_update": "2025-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04947241", "title": "Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04969861", "title": "BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)", "status": "TERMINATED", "last_update": "2023-01-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04973904", "title": "Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04974827", "title": "A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04978012", "title": "Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy", "status": "UNKNOWN", "last_update": "2022-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04984733", "title": "Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer", "status": "COMPLETED", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992988", "title": "Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial", "status": "UNKNOWN", "last_update": "2021-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04995120", "title": "Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04999202", "title": "A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults", "status": "TERMINATED", "last_update": "2025-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05027204", "title": "A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)", "status": "UNKNOWN", "last_update": "2022-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05060432", "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-06-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061537", "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05077709", "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081609", "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05084677", "title": "Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer", "status": "UNKNOWN", "last_update": "2024-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05094804", "title": "A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents", "status": "UNKNOWN", "last_update": "2023-11-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05119296", "title": "Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05145907", "title": "Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05213312", "title": "Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC", "status": "UNKNOWN", "last_update": "2022-06-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05213884", "title": "The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC", "status": "COMPLETED", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215574", "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05220748", "title": "RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC", "status": "WITHDRAWN", "last_update": "2023-04-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05229315", "title": "PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05229614", "title": "Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease", "status": "UNKNOWN", "last_update": "2024-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05234606", "title": "A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2022-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259540", "title": "Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma", "status": "UNKNOWN", "last_update": "2022-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259696", "title": "Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)", "status": "COMPLETED", "last_update": "2025-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05265013", "title": "ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05280457", "title": "HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05287113", "title": "Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS \u2265 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311566", "title": "PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer", "status": "UNKNOWN", "last_update": "2022-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311618", "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors", "status": "UNKNOWN", "last_update": "2024-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05327270", "title": "Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05393635", "title": "ITIL-168 in Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2022-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05424432", "title": "Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus", "status": "UNKNOWN", "last_update": "2022-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05431764", "title": "Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05438420", "title": "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05472506", "title": "Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer", "status": "WITHDRAWN", "last_update": "2024-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480384", "title": "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05490719", "title": "A Phase II Study of CRT Combined With QL1706 in ESCC Patients", "status": "UNKNOWN", "last_update": "2024-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05491616", "title": "Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05504642", "title": "Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients", "status": "WITHDRAWN", "last_update": "2023-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05523323", "title": "A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension", "status": "COMPLETED", "last_update": "2026-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05535023", "title": "Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2023-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05563480", "title": "TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05577182", "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05585034", "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05597839", "title": "Study of DF9001 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-10-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05620134", "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05621707", "title": "Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05655663", "title": "Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05659186", "title": "PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer", "status": "UNKNOWN", "last_update": "2022-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05704985", "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708950", "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05724329", "title": "Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05724355", "title": "CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC", "status": "UNKNOWN", "last_update": "2023-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05732662", "title": "SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2023-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05743270", "title": "Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN", "status": "WITHDRAWN", "last_update": "2025-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05802290", "title": "NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN", "status": "COMPLETED", "last_update": "2023-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05821751", "title": "The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors", "status": "UNKNOWN", "last_update": "2023-04-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05829057", "title": "The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1", "status": "UNKNOWN", "last_update": "2024-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05864144", "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05878288", "title": "Deep sequencIng in Cutaneous Squamous CEll caRciNomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05898828", "title": "Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer", "status": "WITHDRAWN", "last_update": "2024-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904496", "title": "A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05929664", "title": "Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery", "status": "SUSPENDED", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05961111", "title": "A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2023-07-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05980598", "title": "TransCon (TC) TLR7/8 Agonist, TC IL-2 \u03b2/\u03b3, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022757", "title": "Study of XNW5004 Tablet in Combination With KEYTRUDA\u00ae (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)", "status": "TERMINATED", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06034860", "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types", "status": "TERMINATED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046482", "title": "Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06052852", "title": "Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06078657", "title": "IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)", "status": "UNKNOWN", "last_update": "2023-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06082167", "title": "Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06095167", "title": "Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC", "status": "NOT_YET_RECRUITING", "last_update": "2023-10-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06095674", "title": "ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study", "status": "UNKNOWN", "last_update": "2023-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06156878", "title": "PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy", "status": "UNKNOWN", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06184841", "title": "HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2023-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06308913", "title": "Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06357858", "title": "ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck", "status": "WITHDRAWN", "last_update": "2024-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06446570", "title": "Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma", "status": "COMPLETED", "last_update": "2024-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469060", "title": "Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06513884", "title": "A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2025-06-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06544655", "title": "A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06557889", "title": "Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06568172", "title": "Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer", "status": "SUSPENDED", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676293", "title": "Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682806", "title": "A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation", "status": "TERMINATED", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06703047", "title": "Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06793761", "title": "A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06806852", "title": "A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06814067", "title": "Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06855212", "title": "Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06894771", "title": "A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)", "status": "COMPLETED", "last_update": "2026-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06900218", "title": "PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957938", "title": "Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07010393", "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016737", "title": "Immunochemotherapy \u00b1 Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07049185", "title": "QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07110558", "title": "Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07196384", "title": "Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07216833", "title": "Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "WITHDRAWN", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07244978", "title": "Neoadjuvant Ivonescimab\uff08AK112\uff09 Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07251062", "title": "A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07320963", "title": "Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07346196", "title": "A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07368985", "title": "Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371897", "title": "Toripalimab \u00b1 Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07379424", "title": "A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07509099", "title": "Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07514767", "title": "Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07529873", "title": "Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07555860", "title": "Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07576725", "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617818", "title": "QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07618624", "title": "BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07623642", "title": "A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07650266", "title": "A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07659678", "title": "CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662720", "title": "A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07741565", "title": "Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07744126", "title": "A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07776340", "title": "Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07797153", "title": "JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07797881", "title": "A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07801027", "title": "A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07807345", "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 10, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06161545", "title": "Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02757391", "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors", "status": "TERMINATED", "last_update": "2020-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03435640", "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies", "status": "TERMINATED", "last_update": "2023-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03578406", "title": "HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer", "status": "COMPLETED", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04139057", "title": "EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC", "status": "COMPLETED", "last_update": "2026-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04936841", "title": "Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-1", "pembrolizumab", "cemiplimab", "nivolumab" ] }, "PD-L1": { "n": 310, "n_observational": 16, "n_active": 116, "n_withdrawn": 14, "trials": [ { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03952065", "title": "IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)", "status": "RECRUITING", "last_update": "2024-06-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04273061", "title": "Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity", "status": "RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04481256", "title": "TGF-\u03b2 And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY", "status": "RECRUITING", "last_update": "2024-07-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821778", "title": "Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821843", "title": "Neoadjuvant Treatment Modalities in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04954599", "title": "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04999761", "title": "AB122 Platform Study", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05319730", "title": "A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05483400", "title": "Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors", "status": "RECRUITING", "last_update": "2025-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05492123", "title": "Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer", "status": "RECRUITING", "last_update": "2024-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777824", "title": "Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy", "status": "RECRUITING", "last_update": "2023-10-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05799144", "title": "pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS\u22651, hrHPV+ Oropharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05877430", "title": "Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2024-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05919030", "title": "A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06016920", "title": "Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022029", "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06081673", "title": "Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC", "status": "RECRUITING", "last_update": "2023-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123884", "title": "BAT1308 Combined with Platinum-Based Chemotherapy\u00b1 Bevacizumab for PDL1-Positive (CPS \u22651) Cervical Cancer", "status": "RECRUITING", "last_update": "2025-02-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161545", "title": "Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06239220", "title": "PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06254911", "title": "Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259552", "title": "A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2024-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06288360", "title": "Neoadjuvant Immunochemotherapy in PD-L1-negative LACC", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06290505", "title": "A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06332755", "title": "Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06444815", "title": "A Study of VET3-TGI in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675214", "title": "Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769152", "title": "A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06788990", "title": "FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06839066", "title": "A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06953089", "title": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07071103", "title": "Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07105592", "title": "A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195734", "title": "Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07213934", "title": "Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07222657", "title": "Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339488", "title": "Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07385001", "title": "A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC", "status": "RECRUITING", "last_update": "2026-02-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07418749", "title": "A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07472153", "title": "PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07700420", "title": "Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07781358", "title": "Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01810913", "title": "Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer", "status": "SUSPENDED", "last_update": "2026-09-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01938612", "title": "A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2021-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01975831", "title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab", "status": "COMPLETED", "last_update": "2022-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02207530", "title": "Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2020-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02262741", "title": "A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2017-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264678", "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02291055", "title": "A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer", "status": "TERMINATED", "last_update": "2023-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318277", "title": "A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)", "status": "COMPLETED", "last_update": "2022-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02319044", "title": "Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2020-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02358031", "title": "A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)", "status": "COMPLETED", "last_update": "2025-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02369874", "title": "Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423863", "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol\u00ae", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02499328", "title": "Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck", "status": "COMPLETED", "last_update": "2026-02-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02520453", "title": "Adjuvant Durvalumab for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2018-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02551159", "title": "Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-10-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "status": "TERMINATED", "last_update": "2024-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02559687", "title": "Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)", "status": "COMPLETED", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02564263", "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02586987", "title": "A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2019-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639065", "title": "A Study of Durvalumab (MEDI4736) in Esophageal Cancer", "status": "COMPLETED", "last_update": "2023-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02643303", "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers", "status": "COMPLETED", "last_update": "2022-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658214", "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02725489", "title": "Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers", "status": "COMPLETED", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02735239", "title": "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer", "status": "COMPLETED", "last_update": "2024-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02827838", "title": "Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer", "status": "TERMINATED", "last_update": "2025-03-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02842125", "title": "Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2020-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02876510", "title": "ACTolog in Patients With Solid Cancers", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02882308", "title": "Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02903914", "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914470", "title": "Carboplatin-cyclophosphamide Combined With Atezolizumab", "status": "COMPLETED", "last_update": "2021-10-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02921269", "title": "Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer", "status": "COMPLETED", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2019-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02955290", "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02993991", "title": "Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity", "status": "WITHDRAWN", "last_update": "2017-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02997332", "title": "Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019003", "title": "Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients", "status": "COMPLETED", "last_update": "2025-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03040999", "title": "Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)", "status": "COMPLETED", "last_update": "2026-02-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03051906", "title": "Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer", "status": "UNKNOWN", "last_update": "2017-11-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03073525", "title": "A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers", "status": "COMPLETED", "last_update": "2023-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03087864", "title": "PDL-1 Targeting in Resectable Oesophageal Cancer", "status": "COMPLETED", "last_update": "2020-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088059", "title": "Biomarker-based Study in R/M SCCHN", "status": "UNKNOWN", "last_update": "2023-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03108495", "title": "Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma", "status": "TERMINATED", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03144778", "title": "Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2021-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162224", "title": "Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2022-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03174275", "title": "Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03181100", "title": "Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03189719", "title": "First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)", "status": "COMPLETED", "last_update": "2024-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212404", "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03215095", "title": "RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03238638", "title": "A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy", "status": "WITHDRAWN", "last_update": "2018-01-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03258554", "title": "Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin", "status": "COMPLETED", "last_update": "2026-08-27", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277482", "title": "Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer", "status": "TERMINATED", "last_update": "2025-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03281369", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03283605", "title": "Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas", "status": "COMPLETED", "last_update": "2026-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289962", "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292250", "title": "Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]", "status": "COMPLETED", "last_update": "2022-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03313804", "title": "Priming Immunotherapy in Advanced Disease With Radiation", "status": "COMPLETED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03340376", "title": "Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer", "status": "UNKNOWN", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03347838", "title": "Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03377400", "title": "Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03381183", "title": "IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386721", "title": "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399071", "title": "Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03410615", "title": "Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03412058", "title": "Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "status": "TERMINATED", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03450967", "title": "Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC", "status": "UNKNOWN", "last_update": "2021-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03452332", "title": "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers", "status": "COMPLETED", "last_update": "2023-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03463161", "title": "Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy", "status": "TERMINATED", "last_update": "2020-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474497", "title": "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03509012", "title": "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03511391", "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03518606", "title": "Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2025-01-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03522584", "title": "Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03529422", "title": "Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556839", "title": "Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03559803", "title": "A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer", "status": "UNKNOWN", "last_update": "2019-01-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03575598", "title": "Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study", "status": "COMPLETED", "last_update": "2023-07-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03612791", "title": "Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03614949", "title": "SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03618134", "title": "Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03618654", "title": "Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-05-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03623646", "title": "Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.", "status": "COMPLETED", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03624231", "title": "Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC", "status": "COMPLETED", "last_update": "2023-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03635164", "title": "Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03653052", "title": "Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03665285", "title": "A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2024-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03673735", "title": "Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC", "status": "WITHDRAWN", "last_update": "2021-05-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03676959", "title": "A Clinical Study of PD-L1 Antibody ZKAB001\uff08Drug Code\uff09 in Recurrent or Metastatic Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03684785", "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2022-04-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03691714", "title": "Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03693014", "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708224", "title": "Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708328", "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03723967", "title": "FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03726775", "title": "Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737968", "title": "Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03738228", "title": "Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer", "status": "COMPLETED", "last_update": "2025-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03739931", "title": "Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-08-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03753919", "title": "Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial", "status": "TERMINATED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03764553", "title": "Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03765918", "title": "Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03769467", "title": "Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)", "status": "TERMINATED", "last_update": "2024-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03777813", "title": "Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03784066", "title": "Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity", "status": "UNKNOWN", "last_update": "2024-07-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03799744", "title": "Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03808857", "title": "A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive", "status": "UNKNOWN", "last_update": "2021-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811652", "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2019-12-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818061", "title": "Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818997", "title": "Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer", "status": "WITHDRAWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03821935", "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829007", "title": "PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC", "status": "COMPLETED", "last_update": "2022-01-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03830866", "title": "Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03843515", "title": "Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction", "status": "UNKNOWN", "last_update": "2021-10-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03844763", "title": "Targeting the Tumor Microenvironment in R/M SCCHN", "status": "UNKNOWN", "last_update": "2020-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03861793", "title": "A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)", "status": "COMPLETED", "last_update": "2024-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03881111", "title": "First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study", "status": "WITHDRAWN", "last_update": "2020-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03933449", "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946358", "title": "Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03983954", "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04001413", "title": "Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients", "status": "WITHDRAWN", "last_update": "2022-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042116", "title": "A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor", "status": "SUSPENDED", "last_update": "2022-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04052204", "title": "Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2021-10-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04054518", "title": "Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2019-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04065269", "title": "ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04096638", "title": "Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116047", "title": "CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04144517", "title": "A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2024-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04150900", "title": "1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04166721", "title": "WaKING: Wnt and checKpoint INhibition in Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04199104", "title": "A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)", "status": "COMPLETED", "last_update": "2026-05-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04210115", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04215471", "title": "NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma", "status": "UNKNOWN", "last_update": "2022-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04220775", "title": "Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2024-11-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04220866", "title": "Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)", "status": "COMPLETED", "last_update": "2025-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230954", "title": "Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer", "status": "TERMINATED", "last_update": "2022-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04231864", "title": "Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2020-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04246489", "title": "Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer", "status": "COMPLETED", "last_update": "2023-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04247282", "title": "Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection", "status": "COMPLETED", "last_update": "2025-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04262388", "title": "A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation", "status": "WITHDRAWN", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04291079", "title": "SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04300647", "title": "A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer", "status": "COMPLETED", "last_update": "2026-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04369937", "title": "HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for \"Intermediate Risk\" HPV-16-associated Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04405349", "title": "Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer", "status": "COMPLETED", "last_update": "2023-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04428047", "title": "Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04428151", "title": "Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432597", "title": "HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04442126", "title": "A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447612", "title": "Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460066", "title": "A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2022-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477759", "title": "Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04489888", "title": "A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)", "status": "COMPLETED", "last_update": "2025-06-19", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04494009", "title": "PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504669", "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04521686", "title": "Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04540211", "title": "A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04543617", "title": "A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550260", "title": "Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04551950", "title": "Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)", "status": "COMPLETED", "last_update": "2024-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556669", "title": "Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors", "status": "UNKNOWN", "last_update": "2021-05-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04564482", "title": "PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer", "status": "UNKNOWN", "last_update": "2024-03-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04568200", "title": "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623333", "title": "A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer", "status": "UNKNOWN", "last_update": "2020-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04625543", "title": "Neoadjuvant Immunotherapy to ESCC", "status": "WITHDRAWN", "last_update": "2022-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665843", "title": "A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04713891", "title": "A Study of KF-0210 in Advanced Solid Tumors Patients", "status": "COMPLETED", "last_update": "2024-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04732494", "title": "Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04795713", "title": "Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04800978", "title": "Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy", "status": "UNKNOWN", "last_update": "2021-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04831320", "title": "Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04851132", "title": "Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-06-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862455", "title": "NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04939480", "title": "Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN", "status": "COMPLETED", "last_update": "2024-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04949256", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).", "status": "TERMINATED", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04969861", "title": "BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)", "status": "TERMINATED", "last_update": "2023-01-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05001347", "title": "A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ\u00ae) in Patients With Ovarian Cancer and Selected Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007613", "title": "Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-01-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05053737", "title": "Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC", "status": "COMPLETED", "last_update": "2025-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061537", "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063552", "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05068921", "title": "A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy", "status": "UNKNOWN", "last_update": "2021-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05077709", "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091190", "title": "Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05110781", "title": "Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site", "status": "TERMINATED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05222932", "title": "Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05234606", "title": "A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2022-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05249426", "title": "A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer", "status": "COMPLETED", "last_update": "2026-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05253053", "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259319", "title": "Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)", "status": "UNKNOWN", "last_update": "2023-10-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259540", "title": "Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma", "status": "UNKNOWN", "last_update": "2022-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05287113", "title": "Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS \u2265 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05359692", "title": "INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2023-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05386056", "title": "Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05408871", "title": "Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases", "status": "TERMINATED", "last_update": "2024-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05450484", "title": "Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer", "status": "COMPLETED", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05459129", "title": "A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05461794", "title": "Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05523323", "title": "A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension", "status": "COMPLETED", "last_update": "2026-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05577182", "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05655663", "title": "Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05667298", "title": "Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05681039", "title": "Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05715840", "title": "Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy \u00b1 Bevacizumab Versus Placebo Plus Chemotherapy \u00b1Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS\u22651)", "status": "UNKNOWN", "last_update": "2023-02-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05787587", "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06016413", "title": "Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck", "status": "NOT_YET_RECRUITING", "last_update": "2023-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06082167", "title": "Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06090318", "title": "Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss", "status": "WITHDRAWN", "last_update": "2023-10-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06099418", "title": "Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.", "status": "WITHDRAWN", "last_update": "2024-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06118333", "title": "A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06146985", "title": "Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer", "status": "UNKNOWN", "last_update": "2023-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06223308", "title": "A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-01-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06285097", "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06295731", "title": "INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS\u226520 HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06304974", "title": "A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06446570", "title": "Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma", "status": "COMPLETED", "last_update": "2024-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06513884", "title": "A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2025-06-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "status": "TERMINATED", "last_update": "2026-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06557889", "title": "Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06629597", "title": "A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06690216", "title": "Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06724263", "title": "A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06919666", "title": "NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06974734", "title": "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies", "status": "TERMINATED", "last_update": "2026-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07010393", "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07137858", "title": "Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07196384", "title": "Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07230626", "title": "SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07354984", "title": "A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07497074", "title": "JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07565857", "title": "Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625930", "title": "RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07628062", "title": "Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662720", "title": "A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07766889", "title": "Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07769866", "title": "Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07801027", "title": "A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06161545", "title": "Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03108495", "title": "Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma", "status": "TERMINATED", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04556669", "title": "Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors", "status": "UNKNOWN", "last_update": "2021-05-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-L1", "atezolizumab", "durvalumab" ] }, "TROP2": { "n": 33, "n_observational": 2, "n_active": 29, "n_withdrawn": 0, "trials": [ { "nct": "NCT05319730", "title": "A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05838521", "title": "A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05884320", "title": "Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05969041", "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06065371", "title": "Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06329869", "title": "Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06715839", "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780111", "title": "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851663", "title": "Trop2-targeted immunoPET Imaging of Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06923826", "title": "Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06953089", "title": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07063212", "title": "A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07088211", "title": "Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07101432", "title": "Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07216703", "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07256236", "title": "SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07753499", "title": "Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07811752", "title": "Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01631552", "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer", "status": "COMPLETED", "last_update": "2021-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152499", "title": "Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06459180", "title": "A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06465017", "title": "ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer", "status": "TERMINATED", "last_update": "2026-05-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06865677", "title": "Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas", "status": "TERMINATED", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07128693", "title": "A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07348861", "title": "A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07521670", "title": "Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07701681", "title": "Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07778368", "title": "A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07101432", "title": "Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "TROP2", "TACSTD2", "sacituzumab" ] }, "tissue factor": { "n": 41, "n_observational": 4, "n_active": 9, "n_withdrawn": 3, "trials": [ { "nct": "NCT05269381", "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06064877", "title": "A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06597721", "title": "ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06952660", "title": "Ocular Assessments in Patients Treated With Tivdak\u00ae in Recurrent or Metastatic Cervical Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07227168", "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07462377", "title": "A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002515", "title": "Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer", "status": "COMPLETED", "last_update": "2013-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002854", "title": "High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2015-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003657", "title": "High-dose ICE With Amifostine", "status": "COMPLETED", "last_update": "2017-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004048", "title": "Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer", "status": "COMPLETED", "last_update": "2011-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005952", "title": "Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors", "status": "COMPLETED", "last_update": "2013-06-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00007982", "title": "Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer", "status": "COMPLETED", "last_update": "2013-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00014456", "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2013-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00298064", "title": "Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer", "status": "WITHDRAWN", "last_update": "2023-07-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00720304", "title": "Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00982696", "title": "Treatment of Advanced Head and Neck Cancer", "status": "TERMINATED", "last_update": "2014-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01325558", "title": "A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2016-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02001623", "title": "Tisotumab Vedotin (HuMax\u00ae-TF-ADC) Safety Study in Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2021-12-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02011594", "title": "Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma", "status": "WITHDRAWN", "last_update": "2015-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02331134", "title": "Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer", "status": "COMPLETED", "last_update": "2025-05-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02552121", "title": "Tisotumab Vedotin (HuMax\u00ae-TF-ADC) Safety Study in Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02873819", "title": "Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity", "status": "COMPLETED", "last_update": "2022-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03082534", "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03180476", "title": "Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03234465", "title": "Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day", "status": "TERMINATED", "last_update": "2020-11-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03245736", "title": "Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.", "status": "COMPLETED", "last_update": "2021-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03438396", "title": "A Trial of Tisotumab Vedotin in Cervical Cancer", "status": "COMPLETED", "last_update": "2023-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03485209", "title": "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735745", "title": "Transdisciplinary Oral/Oropharyngeal Cancer Research & Care in Head and Neck Cancer (TORCH)", "status": "COMPLETED", "last_update": "2025-01-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03786081", "title": "Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer", "status": "TERMINATED", "last_update": "2026-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03790423", "title": "18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer", "status": "COMPLETED", "last_update": "2020-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03913741", "title": "A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies", "status": "COMPLETED", "last_update": "2022-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04695847", "title": "M1231 in Participants With Solid Tumors", "status": "COMPLETED", "last_update": "2023-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04697628", "title": "Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer", "status": "COMPLETED", "last_update": "2026-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925284", "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)", "status": "COMPLETED", "last_update": "2025-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05228093", "title": "A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis", "status": "UNKNOWN", "last_update": "2022-02-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05433597", "title": "A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC", "status": "NOT_YET_RECRUITING", "last_update": "2022-06-27", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05560035", "title": "The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery", "status": "UNKNOWN", "last_update": "2022-09-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05998941", "title": "A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer", "status": "WITHDRAWN", "last_update": "2023-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06459180", "title": "A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06634030", "title": "Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "tissue factor", "tisotumab", "Tivdak" ] }, "HPV E6/E7": { "n": 99, "n_observational": 14, "n_active": 28, "n_withdrawn": 4, "trials": [ { "nct": "NCT03913117", "title": "Study of Treatment for HPV16+ ASC-US or LSIL", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05307939", "title": "A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05639972", "title": "E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05686226", "title": "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05799144", "title": "pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS\u22651, hrHPV+ Oropharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06007092", "title": "Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06157151", "title": "PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06319963", "title": "A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06658405", "title": "Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06686043", "title": "HPV Vaccine, Imiquimod, and Metformin Combination Trial", "status": "RECRUITING", "last_update": "2024-11-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07454915", "title": "PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002916", "title": "Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer", "status": "COMPLETED", "last_update": "2012-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003977", "title": "Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer", "status": "COMPLETED", "last_update": "2009-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00019110", "title": "Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer", "status": "COMPLETED", "last_update": "2015-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00054041", "title": "Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia", "status": "COMPLETED", "last_update": "2013-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075569", "title": "SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia", "status": "COMPLETED", "last_update": "2018-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00091130", "title": "SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells", "status": "COMPLETED", "last_update": "2013-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00092482", "title": "Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)", "status": "COMPLETED", "last_update": "2017-03-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00121173", "title": "Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia", "status": "COMPLETED", "last_update": "2018-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00155766", "title": "Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)", "status": "UNKNOWN", "last_update": "2005-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00513526", "title": "Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection", "status": "COMPLETED", "last_update": "2023-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00517309", "title": "Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)", "status": "COMPLETED", "last_update": "2017-03-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551187", "title": "A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)", "status": "COMPLETED", "last_update": "2015-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00667563", "title": "Vaccine Therapy in Preventing HPV in HIV-Positive Women in India", "status": "COMPLETED", "last_update": "2024-03-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00685412", "title": "Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3", "status": "COMPLETED", "last_update": "2017-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00788164", "title": "Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia", "status": "COMPLETED", "last_update": "2023-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00973362", "title": "Clinical Evaluation of the APTIMA\u00ae HPV Assay Using the TIGRIS\u00ae System", "status": "COMPLETED", "last_update": "2017-01-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00988559", "title": "Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)", "status": "COMPLETED", "last_update": "2018-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01188850", "title": "Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100", "status": "COMPLETED", "last_update": "2018-08-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01266460", "title": "Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer", "status": "COMPLETED", "last_update": "2020-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01304524", "title": "A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3", "status": "COMPLETED", "last_update": "2018-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01493154", "title": "Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients", "status": "TERMINATED", "last_update": "2018-11-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01824537", "title": "Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study", "status": "COMPLETED", "last_update": "2025-03-19", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928225", "title": "Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL", "status": "COMPLETED", "last_update": "2020-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02002182", "title": "ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer", "status": "COMPLETED", "last_update": "2022-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02065973", "title": "An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101", "status": "COMPLETED", "last_update": "2018-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02128126", "title": "Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer", "status": "COMPLETED", "last_update": "2019-03-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02139267", "title": "Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia", "status": "COMPLETED", "last_update": "2017-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02163057", "title": "Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2021-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02172911", "title": "A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer", "status": "COMPLETED", "last_update": "2021-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02280967", "title": "Prevention of HPV in the School Health Service", "status": "COMPLETED", "last_update": "2017-09-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02405221", "title": "Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer", "status": "COMPLETED", "last_update": "2026-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02501278", "title": "A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer", "status": "WITHDRAWN", "last_update": "2016-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02529930", "title": "An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)", "status": "COMPLETED", "last_update": "2022-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02596243", "title": "Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)", "status": "UNKNOWN", "last_update": "2017-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02750202", "title": "Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts", "status": "COMPLETED", "last_update": "2026-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02858310", "title": "E7 TCR T Cells for Human Papillomavirus-Associated Cancers", "status": "COMPLETED", "last_update": "2026-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02864147", "title": "Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)", "status": "COMPLETED", "last_update": "2024-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02865135", "title": "Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer", "status": "COMPLETED", "last_update": "2024-01-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02866006", "title": "Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer", "status": "COMPLETED", "last_update": "2022-10-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03057912", "title": "A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial Neoplasia\u2160", "status": "UNKNOWN", "last_update": "2017-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03141463", "title": "Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions", "status": "COMPLETED", "last_update": "2018-05-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03185013", "title": "REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)", "status": "COMPLETED", "last_update": "2023-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03284866", "title": "HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03418480", "title": "HARE-40: HPV Anti-CD40 RNA vaccinE", "status": "COMPLETED", "last_update": "2024-02-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "status": "TERMINATED", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03721978", "title": "REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)", "status": "COMPLETED", "last_update": "2024-10-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03870113", "title": "DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2", "status": "UNKNOWN", "last_update": "2019-03-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03911076", "title": "Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL", "status": "TERMINATED", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946358", "title": "Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03979014", "title": "Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia", "status": "COMPLETED", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04015336", "title": "E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer", "status": "TERMINATED", "last_update": "2022-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044950", "title": "A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2020-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04096911", "title": "Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer", "status": "UNKNOWN", "last_update": "2019-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04180215", "title": "A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04247282", "title": "Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection", "status": "COMPLETED", "last_update": "2025-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260126", "title": "Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC", "status": "COMPLETED", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04287868", "title": "Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies", "status": "COMPLETED", "last_update": "2026-06-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04369937", "title": "HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for \"Intermediate Risk\" HPV-16-associated Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04411134", "title": "E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia", "status": "WITHDRAWN", "last_update": "2020-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432597", "title": "HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04452526", "title": "I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04476251", "title": "E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer", "status": "TERMINATED", "last_update": "2021-12-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04534205", "title": "A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04580771", "title": "A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762225", "title": "RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma", "status": "TERMINATED", "last_update": "2022-12-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04800978", "title": "Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy", "status": "UNKNOWN", "last_update": "2021-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892043", "title": "Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04905030", "title": "Education, Immigration and HPV Vaccination: an Informational Randomized Trial", "status": "UNKNOWN", "last_update": "2021-06-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05108870", "title": "TheraT\u00ae Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05173324", "title": "Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial", "status": "NOT_YET_RECRUITING", "last_update": "2022-08-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05232851", "title": "A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05357898", "title": "Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582590", "title": "Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05895370", "title": "HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors", "status": "UNKNOWN", "last_update": "2023-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05973487", "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05996523", "title": "Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06223568", "title": "Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06273553", "title": "A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06358053", "title": "CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06786429", "title": "Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06790966", "title": "Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06882447", "title": "A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06959563", "title": "Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07090174", "title": "CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV", "status": "WITHDRAWN", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07628062", "title": "Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07809997", "title": "Phase I/II Trial of Electroporation-Delivered pBI-4 Vaccine (TriGrid\u2122 PVX4) for Treatment of Women With HPV16-Positive CIN1 or Persistent Infection", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 11, "n_observational": 0, "n_active": 5, "n_withdrawn": 2, "trials": [ { "nct": "NCT05639972", "title": "E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05686226", "title": "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02858310", "title": "E7 TCR T Cells for Human Papillomavirus-Associated Cancers", "status": "COMPLETED", "last_update": "2026-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04015336", "title": "E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer", "status": "TERMINATED", "last_update": "2022-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044950", "title": "A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2020-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04411134", "title": "E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia", "status": "WITHDRAWN", "last_update": "2020-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04476251", "title": "E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer", "status": "TERMINATED", "last_update": "2021-12-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582590", "title": "Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05973487", "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06358053", "title": "CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "HPV16 E7", "HPV E6/E7", "therapeutic HPV vaccine", "VGX-3100", "E7 TCR" ] }, "HER2": { "n": 113, "n_observational": 14, "n_active": 54, "n_withdrawn": 5, "trials": [ { "nct": "NCT03740256", "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04620187", "title": "Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05188313", "title": "TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer", "status": "RECRUITING", "last_update": "2022-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05408845", "title": "Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786716", "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05965479", "title": "Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05969041", "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06155396", "title": "A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer", "status": "RECRUITING", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06293898", "title": "Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06330064", "title": "A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06500052", "title": "A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06715839", "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760819", "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06993844", "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07051486", "title": "A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer", "status": "RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070466", "title": "Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07109726", "title": "A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07192068", "title": "Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07524322", "title": "Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617805", "title": "EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07815522", "title": "Abiraterone With Dalpiciclib in Salivary Gland Carcinoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00095563", "title": "Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers", "status": "COMPLETED", "last_update": "2017-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00126607", "title": "Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer", "status": "TERMINATED", "last_update": "2013-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00239200", "title": "Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus", "status": "TERMINATED", "last_update": "2008-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00291473", "title": "Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers", "status": "COMPLETED", "last_update": "2009-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00371566", "title": "A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer", "status": "COMPLETED", "last_update": "2010-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00387127", "title": "Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer", "status": "COMPLETED", "last_update": "2015-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00498953", "title": "Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx", "status": "COMPLETED", "last_update": "2018-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00680901", "title": "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01171924", "title": "A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors", "status": "COMPLETED", "last_update": "2016-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191697", "title": "CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2025-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01196390", "title": "Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01598077", "title": "A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01774851", "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", "status": "TERMINATED", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928290", "title": "Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02025985", "title": "Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies", "status": "COMPLETED", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02051751", "title": "A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02069730", "title": "A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes", "status": "COMPLETED", "last_update": "2026-01-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02120911", "title": "Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2020-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205463", "title": "KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer", "status": "WITHDRAWN", "last_update": "2014-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264678", "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274012", "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment", "status": "WITHDRAWN", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02344810", "title": "C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer", "status": "WITHDRAWN", "last_update": "2023-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02358863", "title": "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach", "status": "TERMINATED", "last_update": "2018-09-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02662348", "title": "T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System", "status": "UNKNOWN", "last_update": "2016-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689284", "title": "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954536", "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer", "status": "COMPLETED", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088059", "title": "Biomarker-based Study in R/M SCCHN", "status": "UNKNOWN", "last_update": "2023-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03169764", "title": "QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy", "status": "WITHDRAWN", "last_update": "2025-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03185988", "title": "Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System", "status": "UNKNOWN", "last_update": "2019-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2021-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03602079", "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene", "status": "COMPLETED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03746431", "title": "A Phase 1 Study of [225Ac]-FPI-1434 Injection", "status": "TERMINATED", "last_update": "2026-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03821233", "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers", "status": "COMPLETED", "last_update": "2025-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924466", "title": "Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients", "status": "UNKNOWN", "last_update": "2024-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152499", "title": "Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04319757", "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors", "status": "COMPLETED", "last_update": "2024-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "status": "UNKNOWN", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508686", "title": "Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)", "status": "UNKNOWN", "last_update": "2021-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579380", "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04584008", "title": "Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639219", "title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "status": "UNKNOWN", "last_update": "2024-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665921", "title": "A Study of SGN-STNV in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04757363", "title": "A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170256", "title": "Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients", "status": "UNKNOWN", "last_update": "2022-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480384", "title": "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05619016", "title": "[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors", "status": "UNKNOWN", "last_update": "2022-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05898373", "title": "Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC", "status": "UNKNOWN", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06003231", "title": "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06063018", "title": "RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer", "status": "UNKNOWN", "last_update": "2023-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06519110", "title": "Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations", "status": "UNKNOWN", "last_update": "2024-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07036185", "title": "A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172217", "title": "The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07631871", "title": "An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07631884", "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07801027", "title": "A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07617805", "title": "EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "HER2", "ERBB2" ] } }, "by_drug": { "ADEBRELIMAB": { "n": 45, "n_observational": 0, "n_active": 39, "n_withdrawn": 1, "trials": [ { "nct": "NCT03736863", "title": "A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06092957", "title": "Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy", "status": "RECRUITING", "last_update": "2023-12-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06339619", "title": "Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06349889", "title": "Adebrelimab and Chemoradiotherapy in High-risk LANPC", "status": "RECRUITING", "last_update": "2025-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06452602", "title": "Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06455410", "title": "GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06474468", "title": "A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2025-01-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06510660", "title": "Adebrelimab \u00b1Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06663059", "title": "Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study", "status": "RECRUITING", "last_update": "2024-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675214", "title": "Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06869213", "title": "A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06885814", "title": "Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07007364", "title": "Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial", "status": "RECRUITING", "last_update": "2025-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07055841", "title": "Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07059221", "title": "A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07105592", "title": "A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07168200", "title": "A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07437898", "title": "Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07452601", "title": "Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07457346", "title": "A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07595770", "title": "Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07638436", "title": "Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07731828", "title": "Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07733830", "title": "Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796113", "title": "Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06146985", "title": "Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer", "status": "UNKNOWN", "last_update": "2023-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06149767", "title": "Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06178211", "title": "Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06198465", "title": "Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma", "status": "UNKNOWN", "last_update": "2024-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06199271", "title": "Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06225921", "title": "Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas", "status": "UNKNOWN", "last_update": "2024-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06237257", "title": "A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer", "status": "UNKNOWN", "last_update": "2024-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06247956", "title": "Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06420908", "title": "Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)", "status": "WITHDRAWN", "last_update": "2025-08-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06464614", "title": "Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.", "status": "UNKNOWN", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06508229", "title": "Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06861777", "title": "Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06861894", "title": "Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07137039", "title": "Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07137858", "title": "Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554768", "title": "Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770672", "title": "An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/\u00b9\u2078F-FDG (2-Deoxy-2-[\u00b9\u2078F]Fluoro-D-glucose) Dual Imaging", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07778732", "title": "Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07780721", "title": "Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07811375", "title": "Perioperative Adebrelimab for Locally Advanced Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB": { "n": 38, "n_observational": 0, "n_active": 6, "n_withdrawn": 3, "trials": [ { "nct": "NCT06648096", "title": "Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06741982", "title": "A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus", "status": "RECRUITING", "last_update": "2024-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06753747", "title": "A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00514943", "title": "BIBW 2992 (Afatinib) in Head & Neck Cancer", "status": "COMPLETED", "last_update": "2016-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01345669", "title": "LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy", "status": "TERMINATED", "last_update": "2017-12-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01345682", "title": "LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy", "status": "COMPLETED", "last_update": "2018-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01415674", "title": "Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients", "status": "COMPLETED", "last_update": "2022-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01427478", "title": "Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2021-06-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01538381", "title": "Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2018-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01721525", "title": "Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)", "status": "COMPLETED", "last_update": "2017-10-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01732640", "title": "A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.", "status": "TERMINATED", "last_update": "2018-07-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01783587", "title": "Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01824823", "title": "Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence", "status": "TERMINATED", "last_update": "2023-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01856478", "title": "LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy", "status": "COMPLETED", "last_update": "2026-01-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02131155", "title": "LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy", "status": "TERMINATED", "last_update": "2019-03-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02145637", "title": "Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02216617", "title": "Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy", "status": "COMPLETED", "last_update": "2017-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274012", "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment", "status": "WITHDRAWN", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02353936", "title": "A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus", "status": "UNKNOWN", "last_update": "2019-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02979977", "title": "Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck", "status": "COMPLETED", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088059", "title": "Biomarker-based Study in R/M SCCHN", "status": "UNKNOWN", "last_update": "2023-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03652233", "title": "Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "WITHDRAWN", "last_update": "2019-06-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03695510", "title": "Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)", "status": "COMPLETED", "last_update": "2022-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940976", "title": "Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)", "status": "UNKNOWN", "last_update": "2019-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04839471", "title": "BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)", "status": "COMPLETED", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04880811", "title": "Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification", "status": "UNKNOWN", "last_update": "2021-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05516589", "title": "Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC", "status": "COMPLETED", "last_update": "2025-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05517330", "title": "Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05865132", "title": "Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction", "status": "UNKNOWN", "last_update": "2023-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05927844", "title": "XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06494189", "title": "Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma", "status": "COMPLETED", "last_update": "2025-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06804850", "title": "Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC", "status": "WITHDRAWN", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06897735", "title": "Exploratory Study of Inhaled Afatinib Dimaleate PK Profile", "status": "TERMINATED", "last_update": "2026-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07010120", "title": "A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07040956", "title": "A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.", "status": "COMPLETED", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB DIMALEATE": { "n": 38, "n_observational": 0, "n_active": 6, "n_withdrawn": 3, "trials": [ { "nct": "NCT06648096", "title": "Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06741982", "title": "A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus", "status": "RECRUITING", "last_update": "2024-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06753747", "title": "A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00514943", "title": "BIBW 2992 (Afatinib) in Head & Neck Cancer", "status": "COMPLETED", "last_update": "2016-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01345669", "title": "LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy", "status": "TERMINATED", "last_update": "2017-12-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01345682", "title": "LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy", "status": "COMPLETED", "last_update": "2018-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01415674", "title": "Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients", "status": "COMPLETED", "last_update": "2022-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01427478", "title": "Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2021-06-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01538381", "title": "Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2018-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01721525", "title": "Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)", "status": "COMPLETED", "last_update": "2017-10-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01732640", "title": "A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.", "status": "TERMINATED", "last_update": "2018-07-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01783587", "title": "Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01824823", "title": "Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence", "status": "TERMINATED", "last_update": "2023-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01856478", "title": "LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy", "status": "COMPLETED", "last_update": "2026-01-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02131155", "title": "LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy", "status": "TERMINATED", "last_update": "2019-03-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02145637", "title": "Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02216617", "title": "Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy", "status": "COMPLETED", "last_update": "2017-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274012", "title": "Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment", "status": "WITHDRAWN", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02353936", "title": "A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus", "status": "UNKNOWN", "last_update": "2019-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02979977", "title": "Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck", "status": "COMPLETED", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088059", "title": "Biomarker-based Study in R/M SCCHN", "status": "UNKNOWN", "last_update": "2023-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03652233", "title": "Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "WITHDRAWN", "last_update": "2019-06-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03695510", "title": "Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)", "status": "COMPLETED", "last_update": "2022-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940976", "title": "Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)", "status": "UNKNOWN", "last_update": "2019-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04839471", "title": "BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)", "status": "COMPLETED", "last_update": "2024-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04880811", "title": "Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification", "status": "UNKNOWN", "last_update": "2021-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05516589", "title": "Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC", "status": "COMPLETED", "last_update": "2025-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05517330", "title": "Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05865132", "title": "Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction", "status": "UNKNOWN", "last_update": "2023-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05927844", "title": "XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06494189", "title": "Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma", "status": "COMPLETED", "last_update": "2025-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06804850", "title": "Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC", "status": "WITHDRAWN", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06897735", "title": "Exploratory Study of Inhaled Afatinib Dimaleate PK Profile", "status": "TERMINATED", "last_update": "2026-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07010120", "title": "A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07040956", "title": "A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.", "status": "COMPLETED", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ALPELISIB": { "n": 13, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06993844", "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602315", "title": "A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2020-12-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01822613", "title": "Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02051751", "title": "A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02282371", "title": "Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)", "status": "COMPLETED", "last_update": "2021-10-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02298595", "title": "Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2017-11-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02537223", "title": "Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-04-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03138070", "title": "A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292250", "title": "Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]", "status": "COMPLETED", "last_update": "2022-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03601507", "title": "Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer", "status": "TERMINATED", "last_update": "2024-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04997902", "title": "Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)", "status": "COMPLETED", "last_update": "2026-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AMIVANTAMAB": { "n": 6, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT06385080", "title": "A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07276399", "title": "A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04945733", "title": "A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05074940", "title": "Amivantamab in Adenoid Cystic Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07062354", "title": "Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "APL-501": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03808857", "title": "A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive", "status": "UNKNOWN", "last_update": "2021-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ATEZOLIZUMAB": { "n": 80, "n_observational": 0, "n_active": 25, "n_withdrawn": 3, "trials": [ { "nct": "NCT04273061", "title": "Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity", "status": "RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04954599", "title": "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05483400", "title": "Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors", "status": "RECRUITING", "last_update": "2025-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05492123", "title": "Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer", "status": "RECRUITING", "last_update": "2024-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05877430", "title": "Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2024-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06254911", "title": "Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06332755", "title": "Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06444815", "title": "A Study of VET3-TGI in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07385001", "title": "A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC", "status": "RECRUITING", "last_update": "2026-02-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01810913", "title": "Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer", "status": "SUSPENDED", "last_update": "2026-09-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423863", "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol\u00ae", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2018-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02876510", "title": "ACTolog in Patients With Solid Cancers", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914470", "title": "Carboplatin-cyclophosphamide Combined With Atezolizumab", "status": "COMPLETED", "last_update": "2021-10-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02921269", "title": "Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer", "status": "COMPLETED", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03073525", "title": "A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers", "status": "COMPLETED", "last_update": "2023-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03087864", "title": "PDL-1 Targeting in Resectable Oesophageal Cancer", "status": "COMPLETED", "last_update": "2020-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03181100", "title": "Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03281369", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289962", "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03313804", "title": "Priming Immunotherapy in Advanced Disease With Radiation", "status": "COMPLETED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03340376", "title": "Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer", "status": "UNKNOWN", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386721", "title": "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399071", "title": "Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03511391", "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556839", "title": "Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03612791", "title": "Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03614949", "title": "SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03693014", "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708224", "title": "Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03738228", "title": "Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer", "status": "COMPLETED", "last_update": "2025-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818061", "title": "Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818997", "title": "Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer", "status": "WITHDRAWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946358", "title": "Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04096638", "title": "Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04166721", "title": "WaKING: Wnt and checKpoint INhibition in Gastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04220775", "title": "Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2024-11-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04300647", "title": "A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer", "status": "COMPLETED", "last_update": "2026-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04405349", "title": "Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer", "status": "COMPLETED", "last_update": "2023-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432597", "title": "HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04442126", "title": "A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477759", "title": "Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504669", "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04540211", "title": "A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04543617", "title": "A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04564482", "title": "PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer", "status": "UNKNOWN", "last_update": "2024-03-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665843", "title": "A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04713891", "title": "A Study of KF-0210 in Advanced Solid Tumors Patients", "status": "COMPLETED", "last_update": "2024-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04939480", "title": "Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN", "status": "COMPLETED", "last_update": "2024-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05001347", "title": "A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ\u00ae) in Patients With Ovarian Cancer and Selected Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007613", "title": "Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-01-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05053737", "title": "Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC", "status": "COMPLETED", "last_update": "2025-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063552", "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05110781", "title": "Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site", "status": "TERMINATED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05222932", "title": "Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05249426", "title": "A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer", "status": "COMPLETED", "last_update": "2026-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05253053", "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259319", "title": "Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)", "status": "UNKNOWN", "last_update": "2023-10-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05459129", "title": "A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)", "status": "COMPLETED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05655663", "title": "Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05681039", "title": "Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06090318", "title": "Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss", "status": "WITHDRAWN", "last_update": "2023-10-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06099418", "title": "Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.", "status": "WITHDRAWN", "last_update": "2024-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07770100", "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AVELUMAB": { "n": 28, "n_observational": 0, "n_active": 8, "n_withdrawn": 1, "trials": [ { "nct": "NCT04954599", "title": "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06869473", "title": "Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)\u22651\u226419.", "status": "RECRUITING", "last_update": "2025-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "status": "TERMINATED", "last_update": "2024-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02875613", "title": "Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer", "status": "TERMINATED", "last_update": "2024-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02938273", "title": "Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)", "status": "COMPLETED", "last_update": "2019-12-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952586", "title": "Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)", "status": "TERMINATED", "last_update": "2021-09-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02999087", "title": "Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03169764", "title": "QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy", "status": "WITHDRAWN", "last_update": "2025-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03260023", "title": "Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03357757", "title": "Avelumab With Valproic Acid in Virus-associated Cancer", "status": "COMPLETED", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399071", "title": "Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03475953", "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors", "status": "UNKNOWN", "last_update": "2023-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03494322", "title": "EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03498378", "title": "Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03800953", "title": "The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03826589", "title": "Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy", "status": "COMPLETED", "last_update": "2025-06-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03844763", "title": "Targeting the Tumor Microenvironment in R/M SCCHN", "status": "UNKNOWN", "last_update": "2020-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04052204", "title": "Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2021-10-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04065555", "title": "Intratumoral Microdosing of TAK-981 in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2022-07-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04601402", "title": "GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy", "status": "COMPLETED", "last_update": "2023-08-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05222932", "title": "Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BALSTILIMAB": { "n": 9, "n_observational": 0, "n_active": 2, "n_withdrawn": 3, "trials": [ { "nct": "NCT06782555", "title": "A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab", "status": "RECRUITING", "last_update": "2025-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03104699", "title": "A Study of AGEN2034 in Advanced Tumors and Cervical Cancer", "status": "COMPLETED", "last_update": "2025-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03495882", "title": "A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)", "status": "COMPLETED", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03894215", "title": "RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer", "status": "TERMINATED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04943627", "title": "Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)", "status": "WITHDRAWN", "last_update": "2022-10-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05033132", "title": "A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer", "status": "WITHDRAWN", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05363709", "title": "BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients", "status": "WITHDRAWN", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06095674", "title": "ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study", "status": "UNKNOWN", "last_update": "2023-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06251973", "title": "A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BINTRAFUSP ALFA": { "n": 9, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT04481256", "title": "TGF-\u03b2 And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY", "status": "RECRUITING", "last_update": "2024-07-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04220775", "title": "Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2024-11-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04246489", "title": "Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer", "status": "COMPLETED", "last_update": "2023-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04247282", "title": "Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection", "status": "COMPLETED", "last_update": "2025-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04396886", "title": "Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC", "status": "COMPLETED", "last_update": "2024-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04428047", "title": "Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04551950", "title": "Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)", "status": "COMPLETED", "last_update": "2024-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04708470", "title": "A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05012098", "title": "Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).", "status": "COMPLETED", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BUDIGALIMAB": { "n": 8, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05005403", "title": "Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07241039", "title": "A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02988960", "title": "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03000257", "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818542", "title": "A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2020-12-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03821935", "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04196283", "title": "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2023-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06158958", "title": "A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BUPARLISIB": { "n": 11, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01527877", "title": "Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck", "status": "UNKNOWN", "last_update": "2012-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01613677", "title": "Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer", "status": "WITHDRAWN", "last_update": "2017-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01626209", "title": "A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01737450", "title": "Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive", "status": "COMPLETED", "last_update": "2019-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01806649", "title": "BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy", "status": "TERMINATED", "last_update": "2021-10-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01816984", "title": "PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-10-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01830504", "title": "A Multicenter Phase II Pilot Open Label", "status": "UNKNOWN", "last_update": "2016-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01833169", "title": "BKM120 for Patients With PI3K-activated Tumors", "status": "COMPLETED", "last_update": "2018-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01852292", "title": "Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy", "status": "TERMINATED", "last_update": "2018-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02113878", "title": "Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04338399", "title": "The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC", "status": "COMPLETED", "last_update": "2025-11-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CADONILIMAB": { "n": 31, "n_observational": 4, "n_active": 24, "n_withdrawn": 0, "trials": [ { "nct": "NCT05687851", "title": "Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05817214", "title": "Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer", "status": "RECRUITING", "last_update": "2024-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941741", "title": "IC Plus Low-dose Radiation Plus Cadonilimab in LANPC", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06232083", "title": "A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06251388", "title": "A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab\uff08AK104\uff09 for Newly Diagnosed Local Advanced Cervical Cancer", "status": "RECRUITING", "last_update": "2024-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06289751", "title": "Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06356688", "title": "A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06444009", "title": "A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06494995", "title": "AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy", "status": "RECRUITING", "last_update": "2025-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998394", "title": "A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer", "status": "RECRUITING", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07104149", "title": "Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer", "status": "RECRUITING", "last_update": "2025-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07400536", "title": "A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063916", "title": "Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05522894", "title": "AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC", "status": "UNKNOWN", "last_update": "2022-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05587374", "title": "Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05732662", "title": "SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2023-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05790200", "title": "Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05824494", "title": "Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors", "status": "UNKNOWN", "last_update": "2023-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05898256", "title": "Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05990231", "title": "Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy", "status": "UNKNOWN", "last_update": "2023-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06023875", "title": "Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06143748", "title": "Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06426797", "title": "Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06455046", "title": "Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer", "status": "UNKNOWN", "last_update": "2024-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06511726", "title": "Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06681285", "title": "Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06714084", "title": "CNCMT\uff1aa Multi-center, Prospective, Single-arm Study", "status": "ENROLLING_BY_INVITATION", "last_update": "2024-12-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06878196", "title": "ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07450963", "title": "Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07649174", "title": "Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CAMRELIZUMAB": { "n": 133, "n_observational": 5, "n_active": 50, "n_withdrawn": 1, "trials": [ { "nct": "NCT03736863", "title": "A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04453826", "title": "Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2020-09-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04944914", "title": "Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069857", "title": "Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients", "status": "RECRUITING", "last_update": "2023-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05182944", "title": "A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC", "status": "RECRUITING", "last_update": "2022-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05507411", "title": "Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC", "status": "RECRUITING", "last_update": "2022-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05624099", "title": "Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.", "status": "RECRUITING", "last_update": "2023-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05772208", "title": "Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05798793", "title": "Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05854849", "title": "Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC", "status": "RECRUITING", "last_update": "2023-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05937438", "title": "Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma", "status": "RECRUITING", "last_update": "2025-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06086457", "title": "PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06092957", "title": "Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy", "status": "RECRUITING", "last_update": "2023-12-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06170710", "title": "Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC", "status": "RECRUITING", "last_update": "2023-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06239727", "title": "Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response", "status": "RECRUITING", "last_update": "2026-03-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06288360", "title": "Neoadjuvant Immunochemotherapy in PD-L1-negative LACC", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06288373", "title": "Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC", "status": "RECRUITING", "last_update": "2024-10-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06289062", "title": "Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06339060", "title": "An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).", "status": "RECRUITING", "last_update": "2024-07-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06354530", "title": "A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-04-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06438627", "title": "Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675214", "title": "Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06811844", "title": "Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC", "status": "RECRUITING", "last_update": "2025-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06869226", "title": "A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070479", "title": "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07162506", "title": "DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07167160", "title": "Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial", "status": "RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332247", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07530094", "title": "Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662681", "title": "Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03099382", "title": "Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2024-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03121716", "title": "A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects", "status": "COMPLETED", "last_update": "2022-07-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03187314", "title": "Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222440", "title": "Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC", "status": "COMPLETED", "last_update": "2019-12-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03427827", "title": "PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03558191", "title": "SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.", "status": "COMPLETED", "last_update": "2024-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03603756", "title": "SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2020-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03671265", "title": "Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC", "status": "UNKNOWN", "last_update": "2019-01-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03707509", "title": "Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766178", "title": "Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03816553", "title": "SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer", "status": "COMPLETED", "last_update": "2023-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03817658", "title": "A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC", "status": "UNKNOWN", "last_update": "2019-01-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03827837", "title": "Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors", "status": "UNKNOWN", "last_update": "2022-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04143984", "title": "Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156698", "title": "Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04188860", "title": "Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy", "status": "COMPLETED", "last_update": "2022-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04221516", "title": "Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225364", "title": "Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04286958", "title": "A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC", "status": "UNKNOWN", "last_update": "2021-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04390945", "title": "Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04393506", "title": "Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2023-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04399785", "title": "Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC", "status": "UNKNOWN", "last_update": "2020-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04405154", "title": "A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer", "status": "UNKNOWN", "last_update": "2020-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04426955", "title": "Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2021-09-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04440917", "title": "Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04506138", "title": "Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508686", "title": "Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)", "status": "UNKNOWN", "last_update": "2021-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510818", "title": "Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)", "status": "UNKNOWN", "last_update": "2020-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04512417", "title": "A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04539600", "title": "Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2021-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04547088", "title": "Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04548271", "title": "Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04586088", "title": "Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure", "status": "UNKNOWN", "last_update": "2023-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04612894", "title": "Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer", "status": "UNKNOWN", "last_update": "2020-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04635956", "title": "Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas", "status": "UNKNOWN", "last_update": "2020-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04649476", "title": "Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04654403", "title": "Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04680988", "title": "A Study of SHR-1210\u00b1 SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer", "status": "COMPLETED", "last_update": "2025-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04767295", "title": "A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)", "status": "UNKNOWN", "last_update": "2021-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04826679", "title": "Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC", "status": "UNKNOWN", "last_update": "2021-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830267", "title": "The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC", "status": "UNKNOWN", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04861467", "title": "Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04866381", "title": "An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody", "status": "UNKNOWN", "last_update": "2021-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04884906", "title": "Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04906993", "title": "Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04922450", "title": "Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04974827", "title": "A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04974944", "title": "First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer", "status": "TERMINATED", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04978012", "title": "Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy", "status": "UNKNOWN", "last_update": "2022-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04984018", "title": "Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade", "status": "UNKNOWN", "last_update": "2021-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05011227", "title": "Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05049681", "title": "Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell", "status": "UNKNOWN", "last_update": "2021-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05097209", "title": "Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05114707", "title": "Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses", "status": "UNKNOWN", "last_update": "2021-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05151549", "title": "A Study of Carilizumab Combined With Concurrent Chemoradiotherapy", "status": "UNKNOWN", "last_update": "2021-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05156970", "title": "Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05176002", "title": "Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183958", "title": "A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05189184", "title": "Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05213884", "title": "The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC", "status": "COMPLETED", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05234905", "title": "H101 Combined With Camrelizumab for Recurrent Cervical Cancer", "status": "UNKNOWN", "last_update": "2022-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05290935", "title": "Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial", "status": "UNKNOWN", "last_update": "2022-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311566", "title": "PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer", "status": "UNKNOWN", "last_update": "2022-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05322499", "title": "Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2022-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05355168", "title": "Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05431764", "title": "Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05476380", "title": "Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05524168", "title": "SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05549466", "title": "Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC", "status": "UNKNOWN", "last_update": "2023-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554276", "title": "Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer", "status": "UNKNOWN", "last_update": "2024-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576272", "title": "A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-11-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05611463", "title": "Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients", "status": "UNKNOWN", "last_update": "2022-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05637268", "title": "Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650216", "title": "Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC\uff08NICE-RT\uff09", "status": "UNKNOWN", "last_update": "2022-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05673577", "title": "Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients", "status": "COMPLETED", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05724355", "title": "CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC", "status": "UNKNOWN", "last_update": "2023-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777707", "title": "Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05910177", "title": "Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin", "status": "UNKNOWN", "last_update": "2024-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06010212", "title": "Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06048926", "title": "Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2023-09-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06055166", "title": "A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors", "status": "UNKNOWN", "last_update": "2023-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06109207", "title": "Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas", "status": "UNKNOWN", "last_update": "2024-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06170697", "title": "Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06231680", "title": "Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)", "status": "UNKNOWN", "last_update": "2024-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06654297", "title": "Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06866951", "title": "A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial", "status": "WITHDRAWN", "last_update": "2025-12-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016737", "title": "Immunochemotherapy \u00b1 Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067450", "title": "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07143292", "title": "A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07236320", "title": "Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC", "status": "COMPLETED", "last_update": "2025-11-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07251062", "title": "A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07312578", "title": "Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy\uff08nCT\uff09 in the Treatment of Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07400094", "title": "Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07432087", "title": "Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07466901", "title": "A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07505186", "title": "Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07555860", "title": "Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07627620", "title": "Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07791602", "title": "Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CEMIPLIMAB": { "n": 42, "n_observational": 0, "n_active": 21, "n_withdrawn": 2, "trials": [ { "nct": "NCT04722523", "title": "A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04954599", "title": "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988074", "title": "Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022029", "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06448026", "title": "Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769698", "title": "A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06902376", "title": "XL092 and Cemiplimab in BRAF WT Thyroid Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06923761", "title": "EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)", "status": "RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06980038", "title": "Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07179315", "title": "A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195734", "title": "Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423863", "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol\u00ae", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03198130", "title": "An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)", "status": "COMPLETED", "last_update": "2020-03-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03257267", "title": "Study of Cemiplimab in Adults With Cervical Cancer", "status": "COMPLETED", "last_update": "2025-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03565783", "title": "Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03669718", "title": "A Randomized Phase 2 Study of Cemiplimab \u00b1 ISA101b in HPV16-Positive OPC", "status": "UNKNOWN", "last_update": "2023-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03684785", "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2022-04-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03916627", "title": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04154943", "title": "Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04238624", "title": "Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04291105", "title": "Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305795", "title": "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398524", "title": "A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC", "status": "UNKNOWN", "last_update": "2024-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "status": "UNKNOWN", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04465487", "title": "Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies", "status": "TERMINATED", "last_update": "2025-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04646005", "title": "Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy", "status": "COMPLETED", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04831450", "title": "Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "WITHDRAWN", "last_update": "2022-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862650", "title": "Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05094804", "title": "A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents", "status": "UNKNOWN", "last_update": "2023-11-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259696", "title": "Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)", "status": "COMPLETED", "last_update": "2025-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05535023", "title": "Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2023-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05864144", "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05878288", "title": "Deep sequencIng in Cutaneous Squamous CEll caRciNomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05929664", "title": "Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery", "status": "SUSPENDED", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06052852", "title": "Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06568172", "title": "Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer", "status": "SUSPENDED", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06855212", "title": "Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07346196", "title": "A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07650266", "title": "A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CETUXIMAB": { "n": 190, "n_observational": 10, "n_active": 29, "n_withdrawn": 5, "trials": [ { "nct": "NCT02128906", "title": "Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04375384", "title": "Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722523", "title": "A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05910827", "title": "A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06448026", "title": "Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06589804", "title": "Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06699212", "title": "A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases", "status": "RECRUITING", "last_update": "2025-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912087", "title": "Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943820", "title": "AK129 Combination Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-06-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07063212", "title": "A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07216105", "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07217028", "title": "Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07441681", "title": "Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003809", "title": "Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004227", "title": "Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx", "status": "TERMINATED", "last_update": "2014-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005814", "title": "Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00084318", "title": "Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck", "status": "COMPLETED", "last_update": "2018-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00089297", "title": "Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00096174", "title": "Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00104910", "title": "Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer", "status": "COMPLETED", "last_update": "2014-12-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00122460", "title": "Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)", "status": "COMPLETED", "last_update": "2014-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00165490", "title": "Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer", "status": "COMPLETED", "last_update": "2014-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00226239", "title": "Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2017-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00251381", "title": "Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2006-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00291707", "title": "Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00319735", "title": "Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas", "status": "COMPLETED", "last_update": "2016-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00343083", "title": "Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)", "status": "COMPLETED", "last_update": "2019-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00381706", "title": "Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397904", "title": "Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin", "status": "COMPLETED", "last_update": "2015-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00409565", "title": "A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2017-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00425425", "title": "Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer", "status": "UNKNOWN", "last_update": "2014-05-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00439608", "title": "Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00502463", "title": "Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial", "status": "COMPLETED", "last_update": "2024-02-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509561", "title": "Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer", "status": "UNKNOWN", "last_update": "2012-12-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00518193", "title": "Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix", "status": "TERMINATED", "last_update": "2011-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00524017", "title": "Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract", "status": "COMPLETED", "last_update": "2020-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00591149", "title": "Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer", "status": "TERMINATED", "last_update": "2017-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00599131", "title": "Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)", "status": "TERMINATED", "last_update": "2015-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00609284", "title": "Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux", "status": "COMPLETED", "last_update": "2020-04-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00622674", "title": "Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2017-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00660218", "title": "A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00661427", "title": "Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2018-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00665392", "title": "Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer", "status": "COMPLETED", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00671437", "title": "Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer", "status": "COMPLETED", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00704639", "title": "Chemoradiation Treatment for Head and Neck Cancer", "status": "COMPLETED", "last_update": "2017-07-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00705016", "title": "Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "status": "COMPLETED", "last_update": "2014-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00713219", "title": "Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2015-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00714649", "title": "Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery", "status": "COMPLETED", "last_update": "2012-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00735345", "title": "Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma", "status": "TERMINATED", "last_update": "2015-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00736944", "title": "Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2020-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738868", "title": "Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2011-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00765011", "title": "TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer", "status": "COMPLETED", "last_update": "2019-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820417", "title": "Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib", "status": "COMPLETED", "last_update": "2009-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00833261", "title": "Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2020-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00851877", "title": "Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2020-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00868491", "title": "Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2024-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00891904", "title": "Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer", "status": "TERMINATED", "last_update": "2016-04-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00906360", "title": "Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck", "status": "TERMINATED", "last_update": "2013-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00908024", "title": "Combination Study of BMS-754807 and Erbitux\u00ae in Subjects With Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2013-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00933387", "title": "A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2016-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00934518", "title": "Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2019-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00939627", "title": "Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00956007", "title": "RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00957411", "title": "Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer", "status": "COMPLETED", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00957853", "title": "Preoperative Treatment With Cetuximab and/or IMC-A12", "status": "COMPLETED", "last_update": "2020-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968435", "title": "Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2016-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00997009", "title": "Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer", "status": "UNKNOWN", "last_update": "2023-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01009346", "title": "RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN", "status": "TERMINATED", "last_update": "2018-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01015664", "title": "Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "TERMINATED", "last_update": "2012-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01034189", "title": "Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer", "status": "UNKNOWN", "last_update": "2009-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01081041", "title": "A Study in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2019-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01087970", "title": "A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01099358", "title": "Study in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2019-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01133665", "title": "Cetuximab and Lenalidomide in Head and Neck", "status": "COMPLETED", "last_update": "2014-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01166035", "title": "Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2010-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01177956", "title": "A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck", "status": "COMPLETED", "last_update": "2014-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01212627", "title": "Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer", "status": "TERMINATED", "last_update": "2021-02-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01216020", "title": "Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer", "status": "TERMINATED", "last_update": "2018-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01218048", "title": "ERBITUX\u00ae Followed by Adjuvant Treatment With Chemoradiation and ERBITUX\u00ae for Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2018-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01221753", "title": "Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study", "status": "TERMINATED", "last_update": "2017-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01230476", "title": "Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma", "status": "TERMINATED", "last_update": "2019-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01252628", "title": "Phase 1 and 2 Study of PX-866 and Cetuximab", "status": "COMPLETED", "last_update": "2018-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01254617", "title": "Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer", "status": "COMPLETED", "last_update": "2020-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01255800", "title": "Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01262859", "title": "Pilot Study for Locally Advanced Head and Neck Cancer", "status": "WITHDRAWN", "last_update": "2014-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01301248", "title": "Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck", "status": "UNKNOWN", "last_update": "2011-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01302834", "title": "Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer", "status": "COMPLETED", "last_update": "2026-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01316757", "title": "Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2018-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01326468", "title": "Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer", "status": "WITHDRAWN", "last_update": "2025-09-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01326923", "title": "Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2020-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01332266", "title": "E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2022-01-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01434394", "title": "Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer", "status": "COMPLETED", "last_update": "2017-08-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01437449", "title": "Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "status": "COMPLETED", "last_update": "2024-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01440270", "title": "Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer", "status": "COMPLETED", "last_update": "2020-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01445405", "title": "Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer", "status": "COMPLETED", "last_update": "2019-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01451632", "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers", "status": "COMPLETED", "last_update": "2016-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01472653", "title": "Treatment Selection According to Skin Reaction to Cetuximab", "status": "UNKNOWN", "last_update": "2011-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01488318", "title": "Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2018-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01553032", "title": "Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux\u00ae (HICARE)", "status": "COMPLETED", "last_update": "2022-05-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01566435", "title": "Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer", "status": "COMPLETED", "last_update": "2020-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01581970", "title": "Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer", "status": "COMPLETED", "last_update": "2019-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602315", "title": "A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2020-12-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01637194", "title": "Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer", "status": "COMPLETED", "last_update": "2012-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01693159", "title": "Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades", "status": "UNKNOWN", "last_update": "2017-09-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01737450", "title": "Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive", "status": "COMPLETED", "last_update": "2019-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01744340", "title": "A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01758731", "title": "Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History", "status": "COMPLETED", "last_update": "2019-09-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01787006", "title": "Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01790516", "title": "Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer", "status": "TERMINATED", "last_update": "2014-10-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01810913", "title": "Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer", "status": "SUSPENDED", "last_update": "2026-09-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01836029", "title": "Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2019-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01864772", "title": "Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC", "status": "COMPLETED", "last_update": "2022-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01874171", "title": "Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC", "status": "UNKNOWN", "last_update": "2017-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01884259", "title": "Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN", "status": "COMPLETED", "last_update": "2022-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01884623", "title": "Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer", "status": "COMPLETED", "last_update": "2024-02-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01931150", "title": "Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT", "status": "COMPLETED", "last_update": "2017-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01969877", "title": "A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.", "status": "COMPLETED", "last_update": "2020-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01979211", "title": "Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2024-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02054442", "title": "A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck", "status": "UNKNOWN", "last_update": "2021-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02057107", "title": "SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN", "status": "COMPLETED", "last_update": "2023-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02110082", "title": "Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2017-04-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02124707", "title": "Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN", "status": "COMPLETED", "last_update": "2020-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02124850", "title": "A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab", "status": "TERMINATED", "last_update": "2019-10-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02177838", "title": "Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer", "status": "TERMINATED", "last_update": "2021-04-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02281955", "title": "De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study", "status": "COMPLETED", "last_update": "2025-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02282371", "title": "Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)", "status": "COMPLETED", "last_update": "2021-10-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02358031", "title": "A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)", "status": "COMPLETED", "last_update": "2025-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02429089", "title": "Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck", "status": "TERMINATED", "last_update": "2020-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02438995", "title": "Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck", "status": "TERMINATED", "last_update": "2021-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02507154", "title": "Reactivating NK Cells in Treating Refractory Head and Neck Cancer", "status": "UNKNOWN", "last_update": "2018-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02555644", "title": "A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer", "status": "COMPLETED", "last_update": "2019-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02627274", "title": "A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)", "status": "COMPLETED", "last_update": "2022-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02633176", "title": "Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2015-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02633800", "title": "Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )", "status": "TERMINATED", "last_update": "2019-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02636088", "title": "Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2018-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02707588", "title": "Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC", "status": "COMPLETED", "last_update": "2023-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02764593", "title": "Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2022-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02817113", "title": "Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer", "status": "TERMINATED", "last_update": "2021-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02938273", "title": "Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)", "status": "COMPLETED", "last_update": "2019-12-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03024489", "title": "Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03051906", "title": "Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer", "status": "UNKNOWN", "last_update": "2017-11-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03067610", "title": "Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer", "status": "COMPLETED", "last_update": "2022-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03070366", "title": "Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088059", "title": "Biomarker-based Study in R/M SCCHN", "status": "UNKNOWN", "last_update": "2023-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03254927", "title": "A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2023-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2021-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03349710", "title": "Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-08-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386838", "title": "An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck", "status": "WITHDRAWN", "last_update": "2019-04-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03422536", "title": "Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03498378", "title": "Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03524326", "title": "Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03532737", "title": "Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer", "status": "UNKNOWN", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03646461", "title": "Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC", "status": "TERMINATED", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03887442", "title": "Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1\u00ba Chemotherapy", "status": "TERMINATED", "last_update": "2021-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03953976", "title": "INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy", "status": "COMPLETED", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04065555", "title": "Intratumoral Microdosing of TAK-981 in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2022-07-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04091867", "title": "sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC", "status": "COMPLETED", "last_update": "2025-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04106362", "title": "Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2023-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229459", "title": "Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278092", "title": "Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282109", "title": "Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)", "status": "COMPLETED", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04290546", "title": "CIML NK Cell in Head & Neck Cancer", "status": "COMPLETED", "last_update": "2026-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04349267", "title": "Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04428151", "title": "Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508829", "title": "Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy", "status": "UNKNOWN", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04616196", "title": "Study of NKTR 255 in Combination With Cetuximab in Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04670679", "title": "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04856631", "title": "A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04883281", "title": "A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05249426", "title": "A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer", "status": "COMPLETED", "last_update": "2026-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05265013", "title": "ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05674526", "title": "A Phase 1b Study of WU-NK-101 in Combination With Cetuximab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816785", "title": "Pilot Study of Imatinib Cetuximab Combo for H & N Cancer", "status": "COMPLETED", "last_update": "2026-09-04", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05930938", "title": "Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer", "status": "TERMINATED", "last_update": "2025-05-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046482", "title": "Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06081582", "title": "Toripalimab in Combined With Cetuximab\uff0cChemotherapy for Conversion Therapy of Locally Nonresectable OCSCC", "status": "UNKNOWN", "last_update": "2023-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06332092", "title": "FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06508606", "title": "AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06728618", "title": "Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06806852", "title": "A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06855212", "title": "Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06919666", "title": "NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07320690", "title": "De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07509099", "title": "Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07618624", "title": "BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CETUXIMAB SAROTALOCAN": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06699212", "title": "A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases", "status": "RECRUITING", "last_update": "2025-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05265013", "title": "ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CONTUSUGENE LADENOVEC": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003257", "title": "Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer", "status": "UNKNOWN", "last_update": "2013-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017173", "title": "S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat", "status": "TERMINATED", "last_update": "2012-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00064103", "title": "Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx", "status": "COMPLETED", "last_update": "2013-01-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410865", "title": "Wild Type p53 Adenovirus for Oral Premalignancies", "status": "TERMINATED", "last_update": "2011-12-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02842125", "title": "Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2020-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "COPANLISIB": { "n": 4, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02822482", "title": "Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss", "status": "TERMINATED", "last_update": "2021-03-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735628", "title": "An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04462471", "title": "Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers", "status": "COMPLETED", "last_update": "2025-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "COSIBELIMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT03212404", "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CUDC-101": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01171924", "title": "A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors", "status": "COMPLETED", "last_update": "2016-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01384799", "title": "Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer", "status": "COMPLETED", "last_update": "2018-02-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DACOMITINIB": { "n": 7, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00768664", "title": "Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2021-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01116843", "title": "Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment", "status": "COMPLETED", "last_update": "2015-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01449201", "title": "PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2014-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01484847", "title": "A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2015-07-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01608022", "title": "A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus", "status": "COMPLETED", "last_update": "2016-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01737008", "title": "Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2016-06-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04946968", "title": "Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DATOPOTAMAB DERUXTECAN": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DEPATUXIZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02365662", "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor", "status": "TERMINATED", "last_update": "2018-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DEPATUXIZUMAB MAFODOTIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02365662", "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor", "status": "TERMINATED", "last_update": "2018-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DISITAMAB VEDOTIN": { "n": 5, "n_observational": 0, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06155396", "title": "A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer", "status": "RECRUITING", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06558682", "title": "Neoadjuvant Therapy in Cervical Cancer", "status": "RECRUITING", "last_update": "2025-04-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06003231", "title": "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172217", "title": "The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DOSTARLIMAB": { "n": 14, "n_observational": 0, "n_active": 11, "n_withdrawn": 0, "trials": [ { "nct": "NCT04681469", "title": "Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC", "status": "RECRUITING", "last_update": "2022-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06023862", "title": "A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06256588", "title": "A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07336147", "title": "Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07408063", "title": "A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03833479", "title": "TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04068753", "title": "Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04313504", "title": "Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC", "status": "COMPLETED", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04779151", "title": "Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab", "status": "TERMINATED", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05060432", "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-06-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05277051", "title": "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05784012", "title": "Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06062420", "title": "A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06238635", "title": "Dostarlimab and Cobolimab in Advanced Cervical Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DULIGOTUZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01911598", "title": "A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)", "status": "COMPLETED", "last_update": "2017-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DURVALUMAB": { "n": 90, "n_observational": 1, "n_active": 22, "n_withdrawn": 5, "trials": [ { "nct": "NCT04954599", "title": "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06290505", "title": "A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07222657", "title": "Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07700420", "title": "Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01938612", "title": "A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2021-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01975831", "title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab", "status": "COMPLETED", "last_update": "2022-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02207530", "title": "Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2020-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02262741", "title": "A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2017-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264678", "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02291055", "title": "A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer", "status": "TERMINATED", "last_update": "2023-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318277", "title": "A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)", "status": "COMPLETED", "last_update": "2022-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02319044", "title": "Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2020-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02369874", "title": "Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-02-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423863", "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol\u00ae", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02499328", "title": "Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck", "status": "COMPLETED", "last_update": "2026-02-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02520453", "title": "Adjuvant Durvalumab for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02551159", "title": "Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-10-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02586987", "title": "A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2019-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639065", "title": "A Study of Durvalumab (MEDI4736) in Esophageal Cancer", "status": "COMPLETED", "last_update": "2023-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02643303", "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers", "status": "COMPLETED", "last_update": "2022-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658214", "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02725489", "title": "Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers", "status": "COMPLETED", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02735239", "title": "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer", "status": "COMPLETED", "last_update": "2024-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02827838", "title": "Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer", "status": "TERMINATED", "last_update": "2025-03-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02882308", "title": "Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.", "status": "COMPLETED", "last_update": "2020-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02993991", "title": "Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity", "status": "WITHDRAWN", "last_update": "2017-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02997332", "title": "Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019003", "title": "Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients", "status": "COMPLETED", "last_update": "2025-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03051906", "title": "Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer", "status": "UNKNOWN", "last_update": "2017-11-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088059", "title": "Biomarker-based Study in R/M SCCHN", "status": "UNKNOWN", "last_update": "2023-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03144778", "title": "Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2021-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162224", "title": "Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2022-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03174275", "title": "Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03215095", "title": "RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03258554", "title": "Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin", "status": "COMPLETED", "last_update": "2026-08-27", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277482", "title": "Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer", "status": "TERMINATED", "last_update": "2025-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03283605", "title": "Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas", "status": "COMPLETED", "last_update": "2026-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292250", "title": "Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]", "status": "COMPLETED", "last_update": "2022-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03377400", "title": "Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03381183", "title": "IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03410615", "title": "Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "status": "TERMINATED", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03450967", "title": "Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC", "status": "UNKNOWN", "last_update": "2021-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03452332", "title": "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers", "status": "COMPLETED", "last_update": "2023-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03509012", "title": "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03518606", "title": "Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2025-01-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03522584", "title": "Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03529422", "title": "Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03618134", "title": "Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03618654", "title": "Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-05-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03623646", "title": "Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.", "status": "COMPLETED", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03624231", "title": "Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC", "status": "COMPLETED", "last_update": "2023-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03635164", "title": "Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03653052", "title": "Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03673735", "title": "Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC", "status": "WITHDRAWN", "last_update": "2021-05-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03691714", "title": "Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03723967", "title": "FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03726775", "title": "Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737968", "title": "Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03739931", "title": "Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-08-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03753919", "title": "Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial", "status": "TERMINATED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03777813", "title": "Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03784066", "title": "Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity", "status": "UNKNOWN", "last_update": "2024-07-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03799744", "title": "Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829007", "title": "PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC", "status": "COMPLETED", "last_update": "2022-01-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03830866", "title": "Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)", "status": "COMPLETED", "last_update": "2024-07-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03983954", "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04001413", "title": "Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients", "status": "WITHDRAWN", "last_update": "2022-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04054518", "title": "Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2019-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04065269", "title": "ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116047", "title": "CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04231864", "title": "Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2020-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04262388", "title": "A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation", "status": "WITHDRAWN", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447612", "title": "Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504669", "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04521686", "title": "Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550260", "title": "Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04568200", "title": "Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04800978", "title": "Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy", "status": "UNKNOWN", "last_update": "2021-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04851132", "title": "Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-06-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05667298", "title": "Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06446570", "title": "Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma", "status": "COMPLETED", "last_update": "2024-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07565857", "title": "Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625930", "title": "RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENVAFOLIMAB": { "n": 6, "n_observational": 1, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT06055816", "title": "Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06059261", "title": "Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07266493", "title": "Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05552651", "title": "Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05799469", "title": "Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05828381", "title": "Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPRENETAPOPT": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02999893", "title": "A Study of APR-246 in Oesophageal Cancer", "status": "TERMINATED", "last_update": "2021-12-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ERLOTINIB": { "n": 61, "n_observational": 0, "n_active": 1, "n_withdrawn": 3, "trials": [ { "nct": "NCT06997068", "title": "Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00030498", "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction", "status": "COMPLETED", "last_update": "2013-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00030576", "title": "Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2018-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031993", "title": "Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix", "status": "COMPLETED", "last_update": "2013-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00032123", "title": "Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2013-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00045526", "title": "Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049166", "title": "Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049283", "title": "Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-06-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00055770", "title": "Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00055913", "title": "Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00063895", "title": "Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2013-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00076310", "title": "OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00079053", "title": "Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00113347", "title": "Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "COMPLETED", "last_update": "2012-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00140556", "title": "Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-01-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00144976", "title": "Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma", "status": "COMPLETED", "last_update": "2015-03-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00281866", "title": "Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2016-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00304278", "title": "Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00314262", "title": "Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor", "status": "COMPLETED", "last_update": "2014-10-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00392665", "title": "Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck", "status": "TERMINATED", "last_update": "2017-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00392704", "title": "Treatment of Head & Neck Cancer With Chemotherapy and Radiation", "status": "COMPLETED", "last_update": "2013-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00393068", "title": "Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00400374", "title": "Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2", "status": "COMPLETED", "last_update": "2018-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00402779", "title": "Erlotinib Prevention of Oral Cancer (EPOC)", "status": "COMPLETED", "last_update": "2020-04-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00405405", "title": "Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2025-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410826", "title": "Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-05-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00412217", "title": "A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2016-11-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00428194", "title": "Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer", "status": "WITHDRAWN", "last_update": "2017-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00442455", "title": "Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2019-06-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00442507", "title": "Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction", "status": "TERMINATED", "last_update": "2015-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00448240", "title": "Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer", "status": "TERMINATED", "last_update": "2025-03-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00524121", "title": "Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer", "status": "COMPLETED", "last_update": "2016-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00539617", "title": "Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery", "status": "TERMINATED", "last_update": "2020-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00566800", "title": "Erlotinib in Treating Patients With Barrett Esophagus", "status": "UNKNOWN", "last_update": "2013-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00570232", "title": "UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer", "status": "COMPLETED", "last_update": "2015-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00573989", "title": "Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer", "status": "TERMINATED", "last_update": "2019-01-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00601913", "title": "Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2018-07-05", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00603915", "title": "A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer", "status": "COMPLETED", "last_update": "2019-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00686114", "title": "Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2014-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00720304", "title": "Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738751", "title": "Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers", "status": "COMPLETED", "last_update": "2015-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00750555", "title": "Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer", "status": "TERMINATED", "last_update": "2019-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00779389", "title": "Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family", "status": "COMPLETED", "last_update": "2016-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00942734", "title": "Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00954226", "title": "Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer", "status": "COMPLETED", "last_update": "2025-09-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00970502", "title": "Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2017-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01009203", "title": "Temsirolimus (Torisel\u00ae) and Erlotinib (Tarceva\u00ae) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2015-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01064479", "title": "Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2024-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01116336", "title": "Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck", "status": "COMPLETED", "last_update": "2018-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01116622", "title": "Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract", "status": "COMPLETED", "last_update": "2023-10-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01192815", "title": "Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck", "status": "TERMINATED", "last_update": "2020-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01316757", "title": "Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2018-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01332279", "title": "Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy", "status": "WITHDRAWN", "last_update": "2023-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01465815", "title": "Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)", "status": "WITHDRAWN", "last_update": "2014-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01515137", "title": "Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2023-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01561014", "title": "Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction", "status": "COMPLETED", "last_update": "2018-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01927744", "title": "Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02748707", "title": "Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study", "status": "UNKNOWN", "last_update": "2022-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05827614", "title": "Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications", "status": "TERMINATED", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "FINOTONLIMAB": { "n": 6, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT07040072", "title": "Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07248956", "title": "Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07509099", "title": "Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07618624", "title": "BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07751276", "title": "Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07752394", "title": "Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FUTUXIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01417936", "title": "Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy", "status": "COMPLETED", "last_update": "2018-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GEDATOLISIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02069158", "title": "Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor", "status": "COMPLETED", "last_update": "2019-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03065062", "title": "Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors", "status": "SUSPENDED", "last_update": "2026-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "GEFITINIB": { "n": 39, "n_observational": 2, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00015964", "title": "ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck", "status": "COMPLETED", "last_update": "2013-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00024089", "title": "Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00033449", "title": "Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer", "status": "TERMINATED", "last_update": "2013-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049556", "title": "Gefitinib in Treating Patients With Cervical Cancer", "status": "COMPLETED", "last_update": "2013-06-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00068497", "title": "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-01-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00083057", "title": "Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2012-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00088907", "title": "Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer", "status": "TERMINATED", "last_update": "2015-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00093652", "title": "Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer", "status": "TERMINATED", "last_update": "2015-10-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00095836", "title": "Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy", "status": "COMPLETED", "last_update": "2017-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00100945", "title": "Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2016-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00169221", "title": "Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas", "status": "TERMINATED", "last_update": "2011-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00185835", "title": "Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck", "status": "COMPLETED", "last_update": "2010-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193284", "title": "Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer", "status": "COMPLETED", "last_update": "2010-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00195078", "title": "Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer", "status": "TERMINATED", "last_update": "2007-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00206219", "title": "Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)", "status": "COMPLETED", "last_update": "2011-01-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00212108", "title": "A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839", "status": "COMPLETED", "last_update": "2012-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00215995", "title": "Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas", "status": "COMPLETED", "last_update": "2012-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00228488", "title": "Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma", "status": "COMPLETED", "last_update": "2007-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00229723", "title": "IRESSA\u2122 (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2009-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00233636", "title": "Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck", "status": "WITHDRAWN", "last_update": "2011-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00239304", "title": "Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer", "status": "COMPLETED", "last_update": "2007-12-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00242749", "title": "IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma", "status": "COMPLETED", "last_update": "2009-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00242762", "title": "ZD1839 (IRESSA\u2122) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer", "status": "COMPLETED", "last_update": "2011-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00255476", "title": "The IRESSA Novel Head and Neck Chemotherapy Evaluation Study", "status": "COMPLETED", "last_update": "2009-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00258297", "title": "Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00258323", "title": "Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00268346", "title": "Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2016-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00290719", "title": "Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery", "status": "TERMINATED", "last_update": "2014-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00352105", "title": "Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2012-11-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00493025", "title": "Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery", "status": "TERMINATED", "last_update": "2018-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509002", "title": "Iressa Study in Patients With Salivary Gland Cancer", "status": "COMPLETED", "last_update": "2017-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00519077", "title": "Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2016-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00681967", "title": "Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer", "status": "COMPLETED", "last_update": "2010-09-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820417", "title": "Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib", "status": "COMPLETED", "last_update": "2009-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01185158", "title": "A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2023-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01185171", "title": "Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer", "status": "COMPLETED", "last_update": "2023-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01243398", "title": "Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy", "status": "COMPLETED", "last_update": "2012-11-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01291823", "title": "Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer", "status": "UNKNOWN", "last_update": "2011-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01405846", "title": "Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib", "status": "TERMINATED", "last_update": "2016-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ICOTINIB": { "n": 5, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01534585", "title": "Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2018-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01855854", "title": "Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH", "status": "COMPLETED", "last_update": "2019-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01973725", "title": "Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy", "status": "COMPLETED", "last_update": "2023-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02328261", "title": "A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2014-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02375581", "title": "Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer", "status": "UNKNOWN", "last_update": "2016-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IMETELSTAT": { "n": 2, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00101907", "title": "Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2014-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00121628", "title": "A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer", "status": "COMPLETED", "last_update": "2013-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IMGATUZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01046266", "title": "A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2016-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "INAVOLISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB": { "n": 20, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00095563", "title": "Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers", "status": "COMPLETED", "last_update": "2017-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00098631", "title": "Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00114283", "title": "Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2015-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00239200", "title": "Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus", "status": "TERMINATED", "last_update": "2008-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00371566", "title": "A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer", "status": "COMPLETED", "last_update": "2010-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00387127", "title": "Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer", "status": "COMPLETED", "last_update": "2015-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00424255", "title": "Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery", "status": "COMPLETED", "last_update": "2014-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00430781", "title": "Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer", "status": "COMPLETED", "last_update": "2015-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00490061", "title": "Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy", "status": "TERMINATED", "last_update": "2017-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00498953", "title": "Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx", "status": "COMPLETED", "last_update": "2018-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00680901", "title": "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01044433", "title": "Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck", "status": "COMPLETED", "last_update": "2020-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01184482", "title": "Lapatinib and Cetuximab in Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01612351", "title": "Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery", "status": "COMPLETED", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01711658", "title": "TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01947023", "title": "Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB DITOSYLATE": { "n": 20, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00095563", "title": "Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers", "status": "COMPLETED", "last_update": "2017-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00098631", "title": "Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00114283", "title": "Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer", "status": "COMPLETED", "last_update": "2015-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00239200", "title": "Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus", "status": "TERMINATED", "last_update": "2008-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00371566", "title": "A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer", "status": "COMPLETED", "last_update": "2010-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00387127", "title": "Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer", "status": "COMPLETED", "last_update": "2015-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00424255", "title": "Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery", "status": "COMPLETED", "last_update": "2014-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00430781", "title": "Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer", "status": "COMPLETED", "last_update": "2015-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00490061", "title": "Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy", "status": "TERMINATED", "last_update": "2017-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00498953", "title": "Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx", "status": "COMPLETED", "last_update": "2018-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00680901", "title": "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01044433", "title": "Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck", "status": "COMPLETED", "last_update": "2020-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01184482", "title": "Lapatinib and Cetuximab in Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01612351", "title": "Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery", "status": "COMPLETED", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01711658", "title": "TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01947023", "title": "Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "LOMVASTOMIG": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03708328", "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04785820", "title": "A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MARGETUXIMAB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689284", "title": "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03219268", "title": "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms", "status": "COMPLETED", "last_update": "2023-12-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MASOPROCOL": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00057512", "title": "Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck", "status": "COMPLETED", "last_update": "2016-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00154089", "title": "A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia", "status": "COMPLETED", "last_update": "2016-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MATUZUMAB": { "n": 4, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT07814287", "title": "Becotatug Vedotin Plus Pucotenlimab and Platinum Chemotherapy in Locally Advanced Epidermal Growth Factor Receptor (EGFR)-Positive Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00113581", "title": "Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer", "status": "COMPLETED", "last_update": "2014-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00215644", "title": "Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer", "status": "COMPLETED", "last_update": "2018-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07766889", "title": "Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MM-111": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01774851", "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", "status": "TERMINATED", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAZARTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03114319", "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NERATINIB": { "n": 3, "n_observational": 1, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06519110", "title": "Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations", "status": "UNKNOWN", "last_update": "2024-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NIMOTUZUMAB": { "n": 81, "n_observational": 0, "n_active": 29, "n_withdrawn": 6, "trials": [ { "nct": "NCT04821778", "title": "Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821843", "title": "Neoadjuvant Treatment Modalities in Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05717790", "title": "Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2023-02-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05772208", "title": "Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy", "status": "RECRUITING", "last_update": "2023-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06026878", "title": "GNT Induction Treatment in Locally Advanced NPC", "status": "RECRUITING", "last_update": "2023-09-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06410651", "title": "Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429839", "title": "Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients", "status": "RECRUITING", "last_update": "2024-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06509009", "title": "Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06718205", "title": "Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912711", "title": "TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06988956", "title": "Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-05-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070479", "title": "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07101744", "title": "Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial", "status": "RECRUITING", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07105592", "title": "A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07333274", "title": "Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07353723", "title": "Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer", "status": "RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07445048", "title": "Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07457528", "title": "Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07601737", "title": "Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07706985", "title": "Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab \"Immune Sandwich\" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00702481", "title": "Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2023-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00910117", "title": "Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "COMPLETED", "last_update": "2012-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00957086", "title": "Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer", "status": "UNKNOWN", "last_update": "2024-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01074021", "title": "Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2015-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01249352", "title": "A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-03-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01301612", "title": "Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)", "status": "WITHDRAWN", "last_update": "2014-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01336049", "title": "Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2011-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01345084", "title": "Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab", "status": "WITHDRAWN", "last_update": "2025-03-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01402180", "title": "Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy", "status": "UNKNOWN", "last_update": "2011-07-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01425736", "title": "Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2014-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01463605", "title": "Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial", "status": "COMPLETED", "last_update": "2021-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01516996", "title": "Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer", "status": "UNKNOWN", "last_update": "2012-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01616849", "title": "Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2015-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01688700", "title": "Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2012-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01938105", "title": "Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer", "status": "UNKNOWN", "last_update": "2013-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01993784", "title": "Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2013-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02011594", "title": "Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma", "status": "WITHDRAWN", "last_update": "2015-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02012062", "title": "Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC", "status": "COMPLETED", "last_update": "2019-04-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02034968", "title": "Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma", "status": "WITHDRAWN", "last_update": "2015-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02039791", "title": "Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer", "status": "UNKNOWN", "last_update": "2015-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02041819", "title": "Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus", "status": "WITHDRAWN", "last_update": "2015-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02083211", "title": "Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma", "status": "COMPLETED", "last_update": "2015-04-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02095119", "title": "A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer", "status": "COMPLETED", "last_update": "2015-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272699", "title": "Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2021-03-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02293356", "title": "Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2015-08-19", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02705612", "title": "Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer", "status": "UNKNOWN", "last_update": "2016-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02858206", "title": "Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2019-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03025958", "title": "Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03200691", "title": "Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2017-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03413579", "title": "Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom", "status": "COMPLETED", "last_update": "2021-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03469531", "title": "Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer", "status": "UNKNOWN", "last_update": "2018-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03557112", "title": "By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC", "status": "UNKNOWN", "last_update": "2018-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03666221", "title": "Nimotuzumab for Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03708822", "title": "Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766178", "title": "Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03837808", "title": "Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-11-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915132", "title": "Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04207918", "title": "A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04223024", "title": "Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04367909", "title": "A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04456322", "title": "Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508816", "title": "Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508829", "title": "Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy", "status": "UNKNOWN", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04664244", "title": "Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma", "status": "UNKNOWN", "last_update": "2020-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04882462", "title": "Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.", "status": "UNKNOWN", "last_update": "2021-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05024019", "title": "Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery", "status": "UNKNOWN", "last_update": "2021-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05351762", "title": "Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC", "status": "UNKNOWN", "last_update": "2022-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05355168", "title": "Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05606263", "title": "Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer", "status": "UNKNOWN", "last_update": "2023-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05803915", "title": "Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy", "status": "UNKNOWN", "last_update": "2023-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022276", "title": "Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors", "status": "UNKNOWN", "last_update": "2023-09-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06039891", "title": "Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06048913", "title": "Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age", "status": "COMPLETED", "last_update": "2025-07-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06333821", "title": "A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06771596", "title": "Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06781073", "title": "Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma", "status": "COMPLETED", "last_update": "2025-01-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06879691", "title": "A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-17", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07312578", "title": "Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy\uff08nCT\uff09 in the Treatment of Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07354984", "title": "A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07535567", "title": "Postoperative Radiotherapy With Nimotuzumab \u00b1 Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "NIVOLUMAB": { "n": 180, "n_observational": 20, "n_active": 65, "n_withdrawn": 13, "trials": [ { "nct": "NCT03406247", "title": "Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04114136", "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04875611", "title": "Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment", "status": "RECRUITING", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895709", "title": "A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04954599", "title": "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05076760", "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05136196", "title": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05176483", "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317000", "title": "5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05838729", "title": "Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer", "status": "RECRUITING", "last_update": "2025-09-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06019130", "title": "Nivolumab in Children and Adults With Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022861", "title": "A Study to Compare the Efficacy and Safety of LY01015 and Opdivo\u00ae Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06029270", "title": "Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06064097", "title": "A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06170710", "title": "Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC", "status": "RECRUITING", "last_update": "2023-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265285", "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422403", "title": "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06638931", "title": "Agnostic Therapy in Rare Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06823479", "title": "Towards Cure Via Only Ultra-short ICB in CSCC", "status": "RECRUITING", "last_update": "2025-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07152678", "title": "Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07223424", "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07460765", "title": "Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653503", "title": "Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01818323", "title": "Phase I Trial: T4 Immunotherapy of Head and Neck Cancer", "status": "UNKNOWN", "last_update": "2024-10-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02105636", "title": "Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)", "status": "COMPLETED", "last_update": "2022-10-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02124850", "title": "A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab", "status": "TERMINATED", "last_update": "2019-10-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02335918", "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2019-12-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02526017", "title": "Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02569242", "title": "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02636036", "title": "Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors", "status": "COMPLETED", "last_update": "2021-11-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02637531", "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549", "status": "UNKNOWN", "last_update": "2022-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02684253", "title": "Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "COMPLETED", "last_update": "2022-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02741570", "title": "Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2023-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02764593", "title": "Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2022-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02823574", "title": "Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2023-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02829931", "title": "Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas", "status": "COMPLETED", "last_update": "2023-01-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834247", "title": "A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02842125", "title": "Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2020-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02946671", "title": "Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients", "status": "COMPLETED", "last_update": "2020-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02955290", "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03003637", "title": "ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma", "status": "COMPLETED", "last_update": "2023-10-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03012581", "title": "Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03021993", "title": "Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer", "status": "COMPLETED", "last_update": "2025-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03044613", "title": "Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097939", "title": "Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03107182", "title": "Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer", "status": "COMPLETED", "last_update": "2025-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03129061", "title": "Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "status": "COMPLETED", "last_update": "2022-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03132038", "title": "Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162731", "title": "Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03229278", "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma", "status": "COMPLETED", "last_update": "2023-12-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03246958", "title": "Nivolumab Plus Ipilimumab in Thyroid Cancer", "status": "COMPLETED", "last_update": "2025-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03247712", "title": "Neoadjuvant Immunoradiotherapy in Head & Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03267498", "title": "Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)", "status": "COMPLETED", "last_update": "2026-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03278626", "title": "Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2022-03-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03298893", "title": "Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)", "status": "COMPLETED", "last_update": "2025-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03313804", "title": "Priming Immunotherapy in Advanced Disease With Radiation", "status": "COMPLETED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03317327", "title": "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors", "status": "COMPLETED", "last_update": "2025-06-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03342352", "title": "Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)", "status": "WITHDRAWN", "last_update": "2019-12-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03342911", "title": "Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery", "status": "COMPLETED", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03347123", "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)", "status": "TERMINATED", "last_update": "2022-02-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03347838", "title": "Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03349710", "title": "Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-08-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03355560", "title": "Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy", "status": "COMPLETED", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03370276", "title": "Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386838", "title": "An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck", "status": "WITHDRAWN", "last_update": "2019-04-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03390738", "title": "Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy", "status": "WITHDRAWN", "last_update": "2021-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03402737", "title": "SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N", "status": "TERMINATED", "last_update": "2021-02-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03416244", "title": "A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2022-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03435640", "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies", "status": "TERMINATED", "last_update": "2023-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03508570", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis", "status": "COMPLETED", "last_update": "2025-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03511391", "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03521570", "title": "Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544736", "title": "Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03565445", "title": "A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03575234", "title": "Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2019-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03575598", "title": "Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study", "status": "COMPLETED", "last_update": "2023-07-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03576417", "title": "A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03620123", "title": "A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2022-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633110", "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine", "status": "COMPLETED", "last_update": "2022-04-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03646461", "title": "Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC", "status": "TERMINATED", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03652233", "title": "Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "WITHDRAWN", "last_update": "2019-06-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03655444", "title": "Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy", "status": "TERMINATED", "last_update": "2020-12-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03692325", "title": "Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03693014", "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03715946", "title": "Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer", "status": "COMPLETED", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03721757", "title": "CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer", "status": "COMPLETED", "last_update": "2025-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03727061", "title": "Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer", "status": "TERMINATED", "last_update": "2025-03-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735628", "title": "An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03749460", "title": "Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers", "status": "COMPLETED", "last_update": "2023-12-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03758729", "title": "Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.", "status": "WITHDRAWN", "last_update": "2021-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03758781", "title": "IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03764553", "title": "Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03799445", "title": "Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811015", "title": "Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829436", "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers", "status": "COMPLETED", "last_update": "2023-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829722", "title": "Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03843515", "title": "Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction", "status": "UNKNOWN", "last_update": "2021-10-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854032", "title": "Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878979", "title": "Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN", "status": "COMPLETED", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03894891", "title": "Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer", "status": "COMPLETED", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03906526", "title": "A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer", "status": "TERMINATED", "last_update": "2023-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03914300", "title": "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03914443", "title": "A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2025-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03952585", "title": "De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03984357", "title": "Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03987815", "title": "Neoadjuvant Nivolumab for Operable Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03993353", "title": "Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042116", "title": "A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor", "status": "SUSPENDED", "last_update": "2022-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044859", "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04061980", "title": "Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04074967", "title": "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04080804", "title": "Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04180371", "title": "Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229459", "title": "Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04256213", "title": "COL Immunotherapy Before Radiochimio + Ipilimumab", "status": "COMPLETED", "last_update": "2024-12-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282109", "title": "Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)", "status": "COMPLETED", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04326257", "title": "Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy", "status": "COMPLETED", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04349267", "title": "Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458909", "title": "Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer", "status": "TERMINATED", "last_update": "2025-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04503967", "title": "Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer", "status": "UNKNOWN", "last_update": "2020-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514484", "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04570839", "title": "COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.", "status": "COMPLETED", "last_update": "2024-07-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603248", "title": "A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-06-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624113", "title": "Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma", "status": "TERMINATED", "last_update": "2024-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659369", "title": "Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC", "status": "TERMINATED", "last_update": "2024-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704154", "title": "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors", "status": "COMPLETED", "last_update": "2025-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04757363", "title": "A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04785820", "title": "A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04831320", "title": "Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04848116", "title": "Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04891718", "title": "CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia", "status": "WITHDRAWN", "last_update": "2022-07-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892043", "title": "Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04925284", "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)", "status": "COMPLETED", "last_update": "2025-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04943900", "title": "A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors", "status": "COMPLETED", "last_update": "2025-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04984733", "title": "Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer", "status": "COMPLETED", "last_update": "2026-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05027204", "title": "A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)", "status": "UNKNOWN", "last_update": "2022-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05213312", "title": "Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC", "status": "UNKNOWN", "last_update": "2022-06-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05280457", "title": "HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05327270", "title": "Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05472506", "title": "Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer", "status": "WITHDRAWN", "last_update": "2024-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480384", "title": "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05491616", "title": "Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05504642", "title": "Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients", "status": "WITHDRAWN", "last_update": "2023-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05655663", "title": "Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05704985", "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05743270", "title": "Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN", "status": "WITHDRAWN", "last_update": "2025-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05802290", "title": "NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN", "status": "COMPLETED", "last_update": "2023-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05821751", "title": "The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors", "status": "UNKNOWN", "last_update": "2023-04-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05898828", "title": "Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer", "status": "WITHDRAWN", "last_update": "2024-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06034860", "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types", "status": "TERMINATED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06357858", "title": "ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck", "status": "WITHDRAWN", "last_update": "2024-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06544655", "title": "A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07216833", "title": "Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "WITHDRAWN", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07514767", "title": "Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07529873", "title": "Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07576725", "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07741565", "title": "Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "OMIPALISIB": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT02152995", "title": "Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OSIMERTINIB": { "n": 5, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03989115", "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC", "status": "COMPLETED", "last_update": "2023-06-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04868877", "title": "Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05647122", "title": "First in Human Study of AZD9592 in Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PANITUMUMAB": { "n": 41, "n_observational": 0, "n_active": 8, "n_withdrawn": 3, "trials": [ { "nct": "NCT04511078", "title": "Phase II Panitumumab-IRDye800 in Head & Neck Cancer", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183048", "title": "Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-12-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05747625", "title": "(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786924", "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05901545", "title": "Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05945875", "title": "Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer", "status": "RECRUITING", "last_update": "2025-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06819228", "title": "Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004879", "title": "Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2013-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101907", "title": "Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2014-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00446446", "title": "PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)", "status": "COMPLETED", "last_update": "2022-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00454779", "title": "PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response", "status": "COMPLETED", "last_update": "2018-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00460265", "title": "Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer", "status": "COMPLETED", "last_update": "2014-03-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00500760", "title": "Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2018-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00513383", "title": "Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck", "status": "COMPLETED", "last_update": "2017-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00547157", "title": "Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00578071", "title": "Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer", "status": "COMPLETED", "last_update": "2015-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00756444", "title": "A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2018-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00757172", "title": "Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction", "status": "COMPLETED", "last_update": "2016-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00798655", "title": "Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer", "status": "COMPLETED", "last_update": "2017-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820248", "title": "Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer", "status": "COMPLETED", "last_update": "2023-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00836277", "title": "Phase II Study of Irinotecan and Panitumumab", "status": "COMPLETED", "last_update": "2016-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01077999", "title": "Chemoradiation and Panitumumab for Esophageal Cancer", "status": "COMPLETED", "last_update": "2021-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01128387", "title": "Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer", "status": "TERMINATED", "last_update": "2019-12-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01142414", "title": "Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence", "status": "WITHDRAWN", "last_update": "2012-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01158248", "title": "Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer", "status": "UNKNOWN", "last_update": "2010-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01221753", "title": "Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study", "status": "TERMINATED", "last_update": "2017-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01262183", "title": "Radio-chemotherapy With or Without Panitumumab (Vectibix\u00ae) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus", "status": "TERMINATED", "last_update": "2012-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01264328", "title": "Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer", "status": "COMPLETED", "last_update": "2019-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01305772", "title": "Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN", "status": "TERMINATED", "last_update": "2014-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01307956", "title": "Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer", "status": "TERMINATED", "last_update": "2023-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01312493", "title": "Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab", "status": "WITHDRAWN", "last_update": "2015-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01443065", "title": "MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma", "status": "COMPLETED", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01627379", "title": "Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2018-03-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205398", "title": "Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy", "status": "TERMINATED", "last_update": "2019-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02415881", "title": "Panitumumab IRDye800 Optical Imaging Study", "status": "COMPLETED", "last_update": "2021-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02643056", "title": "Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer", "status": "COMPLETED", "last_update": "2021-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03405142", "title": "Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer", "status": "COMPLETED", "last_update": "2022-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03733210", "title": "Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer", "status": "COMPLETED", "last_update": "2023-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04840472", "title": "Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer", "status": "SUSPENDED", "last_update": "2025-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05423197", "title": "89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC", "status": "WITHDRAWN", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07741643", "title": "Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PEMBROLIZUMAB": { "n": 195, "n_observational": 5, "n_active": 94, "n_withdrawn": 8, "trials": [ { "nct": "NCT03526835", "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04370587", "title": "A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2025-10-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04429542", "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-08-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04712851", "title": "Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia", "status": "RECRUITING", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04787042", "title": "Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067", "status": "RECRUITING", "last_update": "2024-11-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04807673", "title": "Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)", "status": "RECRUITING", "last_update": "2022-06-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04954599", "title": "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05025813", "title": "Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2022-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05047094", "title": "Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "status": "RECRUITING", "last_update": "2025-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05208762", "title": "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05286619", "title": "A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)", "status": "RECRUITING", "last_update": "2024-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05358548", "title": "ATATcH Alternating Treatment Plans for Advanced Cancer", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05669430", "title": "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2025-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05784688", "title": "Study of TU2218 in Combination With KEYTRUDA\u00ae(Pembrolizumab) in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05799144", "title": "pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS\u22651, hrHPV+ Oropharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05815927", "title": "Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05838729", "title": "Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer", "status": "RECRUITING", "last_update": "2025-09-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05859074", "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05977907", "title": "Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06102395", "title": "Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC", "status": "RECRUITING", "last_update": "2023-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06137378", "title": "European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]", "status": "RECRUITING", "last_update": "2024-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161545", "title": "Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06266338", "title": "Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06270706", "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06383780", "title": "Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532799", "title": "TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06589804", "title": "Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06636734", "title": "Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06640283", "title": "Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06699212", "title": "A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases", "status": "RECRUITING", "last_update": "2025-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06788990", "title": "FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06868433", "title": "TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06907602", "title": "Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912087", "title": "Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07061977", "title": "Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172256", "title": "CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07213934", "title": "Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07223424", "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07343596", "title": "Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07403136", "title": "Becotatug Vedotin \u00b1 Anti-PD-1 in Pretreated Advanced ESCC", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07405151", "title": "A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07410676", "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07455019", "title": "A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07485296", "title": "Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07501650", "title": "Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07645625", "title": "Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer", "status": "RECRUITING", "last_update": "2026-06-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02376699", "title": "Safety Study of SEA-CD40 in Cancer Patients", "status": "TERMINATED", "last_update": "2023-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02475213", "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer", "status": "COMPLETED", "last_update": "2025-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02538510", "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2024-11-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02559687", "title": "Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)", "status": "COMPLETED", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02575404", "title": "GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients", "status": "COMPLETED", "last_update": "2023-06-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02609503", "title": "Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02626000", "title": "Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)", "status": "COMPLETED", "last_update": "2021-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02641093", "title": "Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02707588", "title": "Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC", "status": "COMPLETED", "last_update": "2023-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02757391", "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors", "status": "TERMINATED", "last_update": "2020-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02775812", "title": "Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2022-06-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02799095", "title": "A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors", "status": "COMPLETED", "last_update": "2025-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02830594", "title": "Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2024-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02841748", "title": "A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02882282", "title": "Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia", "status": "COMPLETED", "last_update": "2025-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2019-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02955290", "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02973997", "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)", "status": "COMPLETED", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03006887", "title": "Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors", "status": "COMPLETED", "last_update": "2021-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03040999", "title": "Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)", "status": "COMPLETED", "last_update": "2026-02-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03058289", "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6", "status": "COMPLETED", "last_update": "2025-02-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03129061", "title": "Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "status": "COMPLETED", "last_update": "2022-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03189719", "title": "First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)", "status": "COMPLETED", "last_update": "2024-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03196232", "title": "Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03236935", "title": "Phase Ib of L-NMMA and Pembrolizumab", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03238638", "title": "A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy", "status": "WITHDRAWN", "last_update": "2018-01-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03342937", "title": "KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer", "status": "COMPLETED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03360890", "title": "Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386357", "title": "Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "TERMINATED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03444376", "title": "The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer", "status": "COMPLETED", "last_update": "2025-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03463161", "title": "Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy", "status": "TERMINATED", "last_update": "2020-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474497", "title": "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03511391", "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03592407", "title": "Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer", "status": "WITHDRAWN", "last_update": "2022-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03621982", "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-06-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03625323", "title": "Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC", "status": "COMPLETED", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03633110", "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine", "status": "COMPLETED", "last_update": "2022-04-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "status": "TERMINATED", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03674567", "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03684785", "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2022-04-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735290", "title": "A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer", "status": "TERMINATED", "last_update": "2022-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03765918", "title": "Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03769467", "title": "Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)", "status": "TERMINATED", "last_update": "2024-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03789097", "title": "Vaccination With Flt3L, Radiation, and Poly-ICLC", "status": "COMPLETED", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03792347", "title": "Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus", "status": "COMPLETED", "last_update": "2023-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03799003", "title": "A Study of ASP1951 in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813836", "title": "Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03823131", "title": "Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat", "status": "TERMINATED", "last_update": "2023-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03881111", "title": "First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study", "status": "WITHDRAWN", "last_update": "2020-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03933449", "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03938337", "title": "Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer", "status": "TERMINATED", "last_update": "2021-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007744", "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04030455", "title": "Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04032704", "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044859", "title": "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04058145", "title": "AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2020-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04083599", "title": "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04150900", "title": "1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04187872", "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis", "status": "TERMINATED", "last_update": "2023-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04199104", "title": "A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)", "status": "COMPLETED", "last_update": "2026-05-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209660", "title": "Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04222972", "title": "A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-03-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230954", "title": "Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer", "status": "TERMINATED", "last_update": "2022-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260126", "title": "Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC", "status": "COMPLETED", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04266730", "title": "Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab", "status": "SUSPENDED", "last_update": "2026-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04305795", "title": "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04357873", "title": "Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations", "status": "COMPLETED", "last_update": "2025-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04369937", "title": "HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for \"Intermediate Risk\" HPV-16-associated Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389177", "title": "Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04428151", "title": "Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432857", "title": "AN0025 and Pembrolizumab Combination in Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04452214", "title": "A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors", "status": "COMPLETED", "last_update": "2023-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04454489", "title": "Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition", "status": "COMPLETED", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04541108", "title": "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04555837", "title": "Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2025-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04609566", "title": "Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04641728", "title": "Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer", "status": "UNKNOWN", "last_update": "2022-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04643379", "title": "Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04652076", "title": "GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "status": "UNKNOWN", "last_update": "2024-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04670679", "title": "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04682431", "title": "A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04811027", "title": "Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04825990", "title": "Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830592", "title": "A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck", "status": "COMPLETED", "last_update": "2025-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862455", "title": "NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer", "status": "TERMINATED", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04879849", "title": "A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers", "status": "COMPLETED", "last_update": "2025-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04895735", "title": "MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04913337", "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies", "status": "UNKNOWN", "last_update": "2024-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04936841", "title": "Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2024-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04943445", "title": "Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers", "status": "COMPLETED", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04969861", "title": "BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)", "status": "TERMINATED", "last_update": "2023-01-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04999202", "title": "A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults", "status": "TERMINATED", "last_update": "2025-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05060432", "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-06-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05077709", "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081609", "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05119296", "title": "Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05145907", "title": "Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215574", "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05220748", "title": "RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC", "status": "WITHDRAWN", "last_update": "2023-04-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05229614", "title": "Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease", "status": "UNKNOWN", "last_update": "2024-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05234606", "title": "A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2022-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05265013", "title": "ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311618", "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors", "status": "UNKNOWN", "last_update": "2024-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05393635", "title": "ITIL-168 in Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2022-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05438420", "title": "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05523323", "title": "A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension", "status": "COMPLETED", "last_update": "2026-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05585034", "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05597839", "title": "Study of DF9001 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-10-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05620134", "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05655663", "title": "Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05708950", "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)", "status": "COMPLETED", "last_update": "2026-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05980598", "title": "TransCon (TC) TLR7/8 Agonist, TC IL-2 \u03b2/\u03b3, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022757", "title": "Study of XNW5004 Tablet in Combination With KEYTRUDA\u00ae (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)", "status": "TERMINATED", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046482", "title": "Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06082167", "title": "Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06308913", "title": "Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06513884", "title": "A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer", "status": "WITHDRAWN", "last_update": "2025-06-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06557889", "title": "Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676293", "title": "Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682806", "title": "A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation", "status": "TERMINATED", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06793761", "title": "A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06806852", "title": "A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06814067", "title": "Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06894771", "title": "A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)", "status": "COMPLETED", "last_update": "2026-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07010393", "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07368985", "title": "Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07509099", "title": "Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07662720", "title": "A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07744126", "title": "A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07801027", "title": "A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07807345", "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PENPULIMAB": { "n": 19, "n_observational": 0, "n_active": 12, "n_withdrawn": 0, "trials": [ { "nct": "NCT05260671", "title": "Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN", "status": "RECRUITING", "last_update": "2023-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06081673", "title": "Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC", "status": "RECRUITING", "last_update": "2023-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06444009", "title": "A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06586242", "title": "Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06788002", "title": "LDRT and Chemoimmunotherapy in NPC With Liver Metastasis", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06886347", "title": "Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943820", "title": "AK129 Combination Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-06-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07381075", "title": "A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04736810", "title": "A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2025-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04952493", "title": "Anlotinib or Penpulimab in Combination With RAI for DTC", "status": "UNKNOWN", "last_update": "2022-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04974398", "title": "A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05137171", "title": "AK105 Combined With Anlotinib in Patients With Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05193617", "title": "Penpulimab Combined With GP \u00b1 Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05265962", "title": "Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade", "status": "UNKNOWN", "last_update": "2022-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05561699", "title": "Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer", "status": "UNKNOWN", "last_update": "2022-09-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05563480", "title": "TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05783921", "title": "A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-07-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807880", "title": "Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07752394", "title": "Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PERTUZUMAB": { "n": 9, "n_observational": 0, "n_active": 7, "n_withdrawn": 1, "trials": [ { "nct": "NCT05188313", "title": "TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer", "status": "RECRUITING", "last_update": "2022-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786716", "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02120911", "title": "Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2020-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03323424", "title": "Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers", "status": "WITHDRAWN", "last_update": "2020-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07550972", "title": "Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "POZIOTINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02216916", "title": "Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy", "status": "UNKNOWN", "last_update": "2019-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292250", "title": "Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]", "status": "COMPLETED", "last_update": "2022-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PUCOTENLIMAB": { "n": 15, "n_observational": 0, "n_active": 15, "n_withdrawn": 0, "trials": [ { "nct": "NCT06959108", "title": "Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06976190", "title": "A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07235566", "title": "MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07586124", "title": "Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07632339", "title": "Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07665190", "title": "Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07814287", "title": "Becotatug Vedotin Plus Pucotenlimab and Platinum Chemotherapy in Locally Advanced Epidermal Growth Factor Receptor (EGFR)-Positive Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06530914", "title": "A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection \u00b1 Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06895369", "title": "The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07354984", "title": "A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07393477", "title": "Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07524413", "title": "Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07545083", "title": "Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07589049", "title": "Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07766889", "title": "Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PYROTINIB": { "n": 3, "n_observational": 1, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06684600", "title": "Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "RETIFANLIMAB": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT02475213", "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer", "status": "COMPLETED", "last_update": "2025-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04634825", "title": "Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer", "status": "TERMINATED", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04989387", "title": "Study of INCA 0186 in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05287113", "title": "Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS \u2265 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05359692", "title": "INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma", "status": "WITHDRAWN", "last_update": "2023-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SACITUZUMAB GOVITECAN": { "n": 12, "n_observational": 0, "n_active": 9, "n_withdrawn": 0, "trials": [ { "nct": "NCT05838521", "title": "A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer", "status": "RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05884320", "title": "Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06065371", "title": "Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06329869", "title": "Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06923826", "title": "Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07063212", "title": "A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07811752", "title": "Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01631552", "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer", "status": "COMPLETED", "last_update": "2021-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06865677", "title": "Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas", "status": "TERMINATED", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07778368", "title": "A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SASANLIMAB": { "n": 9, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04254107", "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer", "status": "TERMINATED", "last_update": "2025-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04458259", "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.", "status": "TERMINATED", "last_update": "2026-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061537", "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05233436", "title": "PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06285097", "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "status": "TERMINATED", "last_update": "2026-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06580938", "title": "A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer", "status": "TERMINATED", "last_update": "2026-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06870487", "title": "A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers", "status": "TERMINATED", "last_update": "2026-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06974734", "title": "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies", "status": "TERMINATED", "last_update": "2026-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SERABELISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04073680", "title": "A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2020-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SERPLULIMAB": { "n": 14, "n_observational": 1, "n_active": 12, "n_withdrawn": 0, "trials": [ { "nct": "NCT05173272", "title": "Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer", "status": "RECRUITING", "last_update": "2023-12-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06354218", "title": "Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age", "status": "RECRUITING", "last_update": "2024-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06601309", "title": "Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2025-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06727617", "title": "Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors", "status": "RECRUITING", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340489", "title": "Serplulimab for Locally Advanced Cervical Cancer", "status": "RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07457528", "title": "Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05444374", "title": "A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer", "status": "UNKNOWN", "last_update": "2022-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05659251", "title": "Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06388135", "title": "Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06419673", "title": "Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06455072", "title": "Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer", "status": "UNKNOWN", "last_update": "2024-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07403435", "title": "Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07446049", "title": "A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SF-1126": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02644122", "title": "SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes", "status": "TERMINATED", "last_update": "2018-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SINTILIMAB": { "n": 80, "n_observational": 3, "n_active": 41, "n_withdrawn": 1, "trials": [ { "nct": "NCT05098119", "title": "Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)", "status": "RECRUITING", "last_update": "2024-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05357846", "title": "PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05495152", "title": "Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-10-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941338", "title": "Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC", "status": "RECRUITING", "last_update": "2023-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06138028", "title": "Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-07-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06170710", "title": "Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC", "status": "RECRUITING", "last_update": "2023-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06190639", "title": "A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC", "status": "RECRUITING", "last_update": "2024-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06240689", "title": "A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood", "status": "RECRUITING", "last_update": "2024-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06391190", "title": "Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer", "status": "RECRUITING", "last_update": "2024-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06413342", "title": "Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06463834", "title": "A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06494943", "title": "Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC", "status": "RECRUITING", "last_update": "2025-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563869", "title": "Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06709417", "title": "A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)", "status": "RECRUITING", "last_update": "2024-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06718205", "title": "Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06787911", "title": "Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer", "status": "RECRUITING", "last_update": "2025-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371611", "title": "Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07424664", "title": "A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07459296", "title": "Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07581821", "title": "Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07751055", "title": "Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03116152", "title": "Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment", "status": "COMPLETED", "last_update": "2021-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03619824", "title": "PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03700476", "title": "Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03748134", "title": "Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )", "status": "COMPLETED", "last_update": "2023-10-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940001", "title": "A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-09-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946969", "title": "Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2022-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03975270", "title": "Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )", "status": "UNKNOWN", "last_update": "2019-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03985046", "title": "Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04065737", "title": "Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization", "status": "UNKNOWN", "last_update": "2019-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04072107", "title": "EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04096911", "title": "Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer", "status": "UNKNOWN", "last_update": "2019-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04212598", "title": "The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer", "status": "COMPLETED", "last_update": "2024-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514835", "title": "A Phase \u2161 Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC", "status": "UNKNOWN", "last_update": "2021-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04548440", "title": "Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04590599", "title": "A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy", "status": "COMPLETED", "last_update": "2023-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602013", "title": "Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2020-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04625543", "title": "Neoadjuvant Immunotherapy to ESCC", "status": "WITHDRAWN", "last_update": "2022-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04718415", "title": "Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04769076", "title": "The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04813406", "title": "Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-03-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04872582", "title": "Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study", "status": "UNKNOWN", "last_update": "2023-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04882462", "title": "Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.", "status": "UNKNOWN", "last_update": "2021-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04917770", "title": "The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04918628", "title": "Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05105672", "title": "A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05136768", "title": "Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)", "status": "UNKNOWN", "last_update": "2021-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05162872", "title": "Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05174325", "title": "Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2021-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05199649", "title": "Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora", "status": "UNKNOWN", "last_update": "2022-01-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05201859", "title": "Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05244798", "title": "Sintilimab Plus NCT or NCRT Versus NCRT for ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2022-10-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05383482", "title": "Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1", "status": "COMPLETED", "last_update": "2025-11-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05417139", "title": "Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study", "status": "UNKNOWN", "last_update": "2022-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05476965", "title": "Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05749042", "title": "A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777707", "title": "Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06015035", "title": "Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer", "status": "COMPLETED", "last_update": "2023-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06078657", "title": "IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)", "status": "UNKNOWN", "last_update": "2023-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06152978", "title": "A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2023-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161909", "title": "Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection", "status": "UNKNOWN", "last_update": "2023-12-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06184841", "title": "HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2023-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06364826", "title": "Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06401447", "title": "TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06403878", "title": "Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer", "status": "UNKNOWN", "last_update": "2024-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06468644", "title": "Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06468670", "title": "Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680115", "title": "Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06900218", "title": "PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06916117", "title": "Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07010393", "title": "Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016737", "title": "Immunochemotherapy \u00b1 Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067450", "title": "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07079410", "title": "Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07088731", "title": "Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07306663", "title": "Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase \u2162 Clinical Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07379424", "title": "A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07756190", "title": "Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07799077", "title": "Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SOCAZOLIMAB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06459687", "title": "Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer", "status": "RECRUITING", "last_update": "2025-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460066", "title": "A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2022-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SPARTALIZUMAB": { "n": 53, "n_observational": 0, "n_active": 24, "n_withdrawn": 1, "trials": [ { "nct": "NCT04778956", "title": "Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2021-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04973306", "title": "Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2022-06-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342792", "title": "Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2022-04-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05511623", "title": "Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer", "status": "RECRUITING", "last_update": "2023-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008054", "title": "A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors", "status": "RECRUITING", "last_update": "2025-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06122493", "title": "Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06170710", "title": "Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC", "status": "RECRUITING", "last_update": "2023-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06437522", "title": "A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475300", "title": "A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06802835", "title": "EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07403136", "title": "Becotatug Vedotin \u00b1 Anti-PD-1 in Pretreated Advanced ESCC", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07472153", "title": "PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01351103", "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands", "status": "COMPLETED", "last_update": "2025-06-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02605967", "title": "Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2022-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03058289", "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6", "status": "COMPLETED", "last_update": "2025-02-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03104699", "title": "A Study of AGEN2034 in Advanced Tumors and Cervical Cancer", "status": "COMPLETED", "last_update": "2025-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03207867", "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2024-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222440", "title": "Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC", "status": "COMPLETED", "last_update": "2019-12-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03301896", "title": "Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies", "status": "TERMINATED", "last_update": "2024-06-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03619824", "title": "PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2018-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03671265", "title": "Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC", "status": "UNKNOWN", "last_update": "2019-01-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03700476", "title": "Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03891953", "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04000529", "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies", "status": "TERMINATED", "last_update": "2025-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04080804", "title": "Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152018", "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.", "status": "TERMINATED", "last_update": "2025-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04171141", "title": "Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.", "status": "TERMINATED", "last_update": "2025-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04193293", "title": "A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04213404", "title": "Ribociclib and Spartalizumab in R/M HNSCC", "status": "UNKNOWN", "last_update": "2022-04-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04368273", "title": "Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.", "status": "UNKNOWN", "last_update": "2020-04-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04544111", "title": "PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04557020", "title": "Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC", "status": "UNKNOWN", "last_update": "2024-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04641871", "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2024-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04672434", "title": "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2024-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821765", "title": "Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830267", "title": "The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC", "status": "UNKNOWN", "last_update": "2024-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04864782", "title": "QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer", "status": "TERMINATED", "last_update": "2024-01-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04943627", "title": "Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)", "status": "WITHDRAWN", "last_update": "2022-10-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05092217", "title": "Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05097209", "title": "Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05201859", "title": "Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05213884", "title": "The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC", "status": "COMPLETED", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05760196", "title": "Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05824468", "title": "Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06647563", "title": "Neoadjuvant Toripalimab + Chemotherapy \u00b1 Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676293", "title": "Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma", "status": "COMPLETED", "last_update": "2024-11-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06900218", "title": "PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07756190", "title": "Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783321", "title": "A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07797881", "title": "A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SUGEMALIMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07711470", "title": "Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TARLOXOTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02449681", "title": "Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin", "status": "TERMINATED", "last_update": "2023-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TASELISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TEBOTELIMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03219268", "title": "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms", "status": "COMPLETED", "last_update": "2023-12-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04634825", "title": "Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer", "status": "TERMINATED", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TISLELIZUMAB": { "n": 131, "n_observational": 5, "n_active": 87, "n_withdrawn": 3, "trials": [ { "nct": "NCT04973306", "title": "Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC", "status": "RECRUITING", "last_update": "2022-06-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342792", "title": "Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2022-04-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05511623", "title": "Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer", "status": "RECRUITING", "last_update": "2023-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05526924", "title": "Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582265", "title": "Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)", "status": "RECRUITING", "last_update": "2024-05-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05595590", "title": "Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer", "status": "RECRUITING", "last_update": "2022-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05758389", "title": "Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors", "status": "RECRUITING", "last_update": "2025-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05862168", "title": "Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma \uff1aA Single-arm, Prospective, Phase II Trial", "status": "RECRUITING", "last_update": "2023-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05919030", "title": "A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05937438", "title": "Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma", "status": "RECRUITING", "last_update": "2025-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05984342", "title": "Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2023-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06056336", "title": "Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06061146", "title": "Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC", "status": "RECRUITING", "last_update": "2023-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093061", "title": "Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06170710", "title": "Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC", "status": "RECRUITING", "last_update": "2023-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06177301", "title": "Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06258811", "title": "Neoadjuvant Immunochemotherapy for LAOSCC", "status": "RECRUITING", "last_update": "2025-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06323369", "title": "Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06354140", "title": "PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY", "status": "RECRUITING", "last_update": "2024-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06383780", "title": "Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.", "status": "RECRUITING", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06430658", "title": "Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer", "status": "RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06446726", "title": "Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06472713", "title": "Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC", "status": "RECRUITING", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06509568", "title": "Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma\uff08CRIS-2 Trial\uff09", "status": "RECRUITING", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06646588", "title": "Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06690476", "title": "Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-11-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06725498", "title": "Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC", "status": "RECRUITING", "last_update": "2024-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06741982", "title": "A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus", "status": "RECRUITING", "last_update": "2024-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07039162", "title": "Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067268", "title": "Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy", "status": "RECRUITING", "last_update": "2025-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070479", "title": "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07205731", "title": "Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07317609", "title": "Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328854", "title": "40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332247", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339488", "title": "Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554456", "title": "A Study of BL-B01D1 in Combination With Tislelizumab \u00b15-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554521", "title": "A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07601737", "title": "Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07700667", "title": "SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07762976", "title": "Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07811752", "title": "Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430843", "title": "A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03469557", "title": "BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03783442", "title": "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924986", "title": "Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03957590", "title": "A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04215978", "title": "Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04666688", "title": "LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04693234", "title": "AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer", "status": "COMPLETED", "last_update": "2025-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04732494", "title": "Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04776590", "title": "Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer", "status": "UNKNOWN", "last_update": "2024-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04814069", "title": "A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma\uff1aThe POTENTIAL Study", "status": "UNKNOWN", "last_update": "2021-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04821765", "title": "Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04833257", "title": "Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC", "status": "COMPLETED", "last_update": "2025-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04870905", "title": "Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04921995", "title": "Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05013268", "title": "Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma", "status": "UNKNOWN", "last_update": "2021-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05211232", "title": "Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238883", "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05245760", "title": "ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer", "status": "WITHDRAWN", "last_update": "2022-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05247619", "title": "A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer", "status": "UNKNOWN", "last_update": "2022-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05310383", "title": "Tislelizumab and Radiotherapy for Recurrent Cervical Cancer", "status": "UNKNOWN", "last_update": "2022-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05343325", "title": "The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05394415", "title": "Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC", "status": "UNKNOWN", "last_update": "2022-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05448885", "title": "Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05461794", "title": "Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05469061", "title": "Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC", "status": "UNKNOWN", "last_update": "2022-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05505877", "title": "Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05516589", "title": "Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC", "status": "COMPLETED", "last_update": "2025-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05517330", "title": "Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05520619", "title": "Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05588219", "title": "Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer", "status": "UNKNOWN", "last_update": "2023-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05596890", "title": "Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients", "status": "UNKNOWN", "last_update": "2022-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05603065", "title": "Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)", "status": "UNKNOWN", "last_update": "2023-06-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05614453", "title": "Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy", "status": "WITHDRAWN", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05628610", "title": "Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05651022", "title": "Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05659186", "title": "PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer", "status": "UNKNOWN", "last_update": "2022-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05724329", "title": "Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777707", "title": "Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807542", "title": "Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05880082", "title": "PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer", "status": "COMPLETED", "last_update": "2025-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904496", "title": "A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05909904", "title": "A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06009861", "title": "Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06010303", "title": "A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06039891", "title": "Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06063018", "title": "RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer", "status": "UNKNOWN", "last_update": "2023-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06130007", "title": "A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2023-11-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06235918", "title": "Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2024-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06303583", "title": "Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma", "status": "ENROLLING_BY_INVITATION", "last_update": "2024-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06331845", "title": "Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06366945", "title": "Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469060", "title": "Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06494189", "title": "Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma", "status": "COMPLETED", "last_update": "2025-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06554028", "title": "Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06673693", "title": "Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06692270", "title": "Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06703047", "title": "Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06728618", "title": "Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06781112", "title": "A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06804850", "title": "Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC", "status": "WITHDRAWN", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06914011", "title": "Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06914687", "title": "Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957938", "title": "Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06965829", "title": "The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06990178", "title": "Adaptive Neoadjuvant Therapy for Esophageal Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-05-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07010120", "title": "A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07019181", "title": "Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07040956", "title": "A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.", "status": "COMPLETED", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07046221", "title": "Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067450", "title": "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07128693", "title": "A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07145931", "title": "Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07248696", "title": "Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07251062", "title": "A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07331428", "title": "MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07373990", "title": "Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07388758", "title": "Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07402538", "title": "Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07678580", "title": "Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07686926", "title": "Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07721103", "title": "Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07733180", "title": "A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07776340", "title": "Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07812467", "title": "Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TOMUZOTUXIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02052960", "title": "CetuGEX\u2122 in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer", "status": "COMPLETED", "last_update": "2021-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TORIPALIMAB": { "n": 159, "n_observational": 5, "n_active": 101, "n_withdrawn": 0, "trials": [ { "nct": "NCT03907826", "title": "PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients", "status": "RECRUITING", "last_update": "2026-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04280822", "title": "Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma", "status": "RECRUITING", "last_update": "2022-10-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04376866", "title": "Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2021-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04453813", "title": "Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2020-09-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04778956", "title": "Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2021-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04807140", "title": "Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)", "status": "RECRUITING", "last_update": "2023-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992559", "title": "A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC", "status": "RECRUITING", "last_update": "2023-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05125055", "title": "Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC", "status": "RECRUITING", "last_update": "2023-11-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05147844", "title": "Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05340491", "title": "Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05628922", "title": "Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT", "status": "RECRUITING", "last_update": "2022-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05877872", "title": "Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2023-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06026878", "title": "GNT Induction Treatment in Locally Advanced NPC", "status": "RECRUITING", "last_update": "2023-09-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06039631", "title": "Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer", "status": "RECRUITING", "last_update": "2023-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084897", "title": "Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy", "status": "RECRUITING", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06092957", "title": "Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy", "status": "RECRUITING", "last_update": "2023-12-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093438", "title": "Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer", "status": "RECRUITING", "last_update": "2025-03-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06170710", "title": "Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC", "status": "RECRUITING", "last_update": "2023-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06187597", "title": "Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)", "status": "RECRUITING", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06208826", "title": "A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06228079", "title": "Adjuvant vs Surgery Only in Early-stage Recurrent NPC", "status": "RECRUITING", "last_update": "2025-07-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06235203", "title": "Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2025-06-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06256224", "title": "Toripalimab Combined With Definitive CCRT for LACC Patients", "status": "RECRUITING", "last_update": "2024-04-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06277050", "title": "Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313450", "title": "De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2024-03-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06323239", "title": "SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06385730", "title": "Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)", "status": "RECRUITING", "last_update": "2024-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06451497", "title": "This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06457503", "title": "A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06472713", "title": "Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC", "status": "RECRUITING", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06509009", "title": "Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06592599", "title": "Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06611137", "title": "SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx", "status": "RECRUITING", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06657144", "title": "A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06675214", "title": "Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06843889", "title": "A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851247", "title": "GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912074", "title": "Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06912711", "title": "TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2025-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06940180", "title": "Toripalimab With Chemotherapy for Sinus Cancer", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070479", "title": "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07086469", "title": "Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07088211", "title": "Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07092696", "title": "Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer", "status": "RECRUITING", "last_update": "2025-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07177794", "title": "Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07209189", "title": "Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07214987", "title": "PDT For Induction Therapy For Head And Neck Cancer", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07258979", "title": "A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07290621", "title": "Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07325539", "title": "LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328841", "title": "Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy", "status": "RECRUITING", "last_update": "2026-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332247", "title": "PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC", "status": "RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340515", "title": "Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial", "status": "RECRUITING", "last_update": "2026-01-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07353723", "title": "Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer", "status": "RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07362979", "title": "Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07423078", "title": "Window of Opportunity in Preserving Laryngeal Function Trial", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07481058", "title": "KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625423", "title": "Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07629817", "title": "Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07706985", "title": "Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab \"Immune Sandwich\" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02915432", "title": "The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC", "status": "UNKNOWN", "last_update": "2021-12-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03474640", "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03854838", "title": "IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.", "status": "UNKNOWN", "last_update": "2022-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03925090", "title": "Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03930498", "title": "Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04005170", "title": "Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer", "status": "COMPLETED", "last_update": "2022-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04006041", "title": "Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-12-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04073784", "title": "Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.", "status": "UNKNOWN", "last_update": "2022-04-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084158", "title": "A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.", "status": "SUSPENDED", "last_update": "2021-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04126460", "title": "High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)", "status": "UNKNOWN", "last_update": "2019-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04164238", "title": "Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients", "status": "UNKNOWN", "last_update": "2019-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04177797", "title": "Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2022-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04177875", "title": "Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer", "status": "UNKNOWN", "last_update": "2019-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229849", "title": "Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2020-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04296747", "title": "Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2020-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04368273", "title": "Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.", "status": "UNKNOWN", "last_update": "2020-04-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04395612", "title": "Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398056", "title": "Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04405622", "title": "Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.", "status": "UNKNOWN", "last_update": "2023-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04446663", "title": "Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447326", "title": "Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2020-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04473716", "title": "Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients", "status": "COMPLETED", "last_update": "2023-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04517214", "title": "Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04523883", "title": "Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)", "status": "UNKNOWN", "last_update": "2021-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04524884", "title": "Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study", "status": "UNKNOWN", "last_update": "2020-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04557020", "title": "Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC", "status": "UNKNOWN", "last_update": "2024-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624308", "title": "Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC", "status": "UNKNOWN", "last_update": "2020-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644250", "title": "Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2020-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04651127", "title": "Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer", "status": "TERMINATED", "last_update": "2026-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04731038", "title": "Combination Therapy for First Line Treatment of Advanced Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04804696", "title": "Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04844385", "title": "Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2024-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04856631", "title": "A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer", "status": "COMPLETED", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04867330", "title": "Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC", "status": "UNKNOWN", "last_update": "2021-04-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04880811", "title": "Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification", "status": "UNKNOWN", "last_update": "2021-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04907370", "title": "PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04947241", "title": "Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04955886", "title": "Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2021-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04973904", "title": "Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer", "status": "UNKNOWN", "last_update": "2021-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992988", "title": "Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial", "status": "UNKNOWN", "last_update": "2021-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04995120", "title": "Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04996758", "title": "Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)", "status": "COMPLETED", "last_update": "2024-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05084677", "title": "Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer", "status": "UNKNOWN", "last_update": "2024-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05163483", "title": "Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer", "status": "UNKNOWN", "last_update": "2023-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05229315", "title": "PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2023-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05341193", "title": "PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-04-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342506", "title": "Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies", "status": "UNKNOWN", "last_update": "2022-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05420597", "title": "Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05424432", "title": "Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus", "status": "UNKNOWN", "last_update": "2022-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05427396", "title": "A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-12-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05484375", "title": "Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2022-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05522985", "title": "Toripalimab-based Neoadjuvant Therapy in LA-HNSCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05635643", "title": "Study of CHS-114 in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05773079", "title": "Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777707", "title": "Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05791136", "title": "Immunotherapy After Radiotherapy in Elderly ESCC", "status": "UNKNOWN", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05803915", "title": "Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy", "status": "UNKNOWN", "last_update": "2023-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05813626", "title": "Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05817201", "title": "Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05860335", "title": "Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer", "status": "UNKNOWN", "last_update": "2024-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05869227", "title": "Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955105", "title": "A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies", "status": "UNKNOWN", "last_update": "2024-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05993858", "title": "Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC", "status": "NOT_YET_RECRUITING", "last_update": "2023-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05996484", "title": "Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma", "status": "UNKNOWN", "last_update": "2023-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06020885", "title": "Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06081582", "title": "Toripalimab in Combined With Cetuximab\uff0cChemotherapy for Conversion Therapy of Locally Nonresectable OCSCC", "status": "UNKNOWN", "last_update": "2023-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06156891", "title": "PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC", "status": "UNKNOWN", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06259721", "title": "Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma", "status": "UNKNOWN", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06281886", "title": "Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma", "status": "COMPLETED", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06378177", "title": "A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06416696", "title": "Toripalimab for High-risk Locally Advanced Cervical Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06419673", "title": "Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06588335", "title": "BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06605131", "title": "GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06647563", "title": "Neoadjuvant Toripalimab + Chemotherapy \u00b1 Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06712888", "title": "Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762158", "title": "NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06861712", "title": "Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06903871", "title": "Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06952621", "title": "Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06987123", "title": "TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07067450", "title": "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07110558", "title": "Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07136519", "title": "Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07236320", "title": "Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC", "status": "COMPLETED", "last_update": "2025-11-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07246330", "title": "Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07272291", "title": "A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07320963", "title": "Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07332221", "title": "Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07363330", "title": "A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07371897", "title": "Toripalimab \u00b1 Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392060", "title": "A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07540390", "title": "GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07555860", "title": "Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07653451", "title": "Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07677475", "title": "MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07778368", "title": "A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796126", "title": "Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB": { "n": 55, "n_observational": 4, "n_active": 26, "n_withdrawn": 3, "trials": [ { "nct": "NCT04620187", "title": "Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05188313", "title": "TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer", "status": "RECRUITING", "last_update": "2022-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05408845", "title": "Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786716", "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05965479", "title": "Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07000253", "title": "Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07216105", "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004163", "title": "Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer", "status": "COMPLETED", "last_update": "2017-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00126607", "title": "Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer", "status": "TERMINATED", "last_update": "2013-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01191697", "title": "CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2025-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01196390", "title": "Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522768", "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer", "status": "COMPLETED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01774851", "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach", "status": "TERMINATED", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928290", "title": "Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer", "status": "COMPLETED", "last_update": "2020-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02120911", "title": "Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma", "status": "COMPLETED", "last_update": "2020-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02205463", "title": "KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer", "status": "WITHDRAWN", "last_update": "2014-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02627274", "title": "A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)", "status": "COMPLETED", "last_update": "2022-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954536", "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer", "status": "COMPLETED", "last_update": "2023-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03185988", "title": "Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System", "status": "UNKNOWN", "last_update": "2019-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2021-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03323424", "title": "Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers", "status": "WITHDRAWN", "last_update": "2020-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409848", "title": "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "status": "TERMINATED", "last_update": "2023-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579380", "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639219", "title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081609", "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05143970", "title": "A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170256", "title": "Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients", "status": "UNKNOWN", "last_update": "2022-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480384", "title": "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05898373", "title": "Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC", "status": "UNKNOWN", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06130007", "title": "A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.", "status": "UNKNOWN", "last_update": "2023-11-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07631884", "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB DERUXTECAN": { "n": 11, "n_observational": 2, "n_active": 10, "n_withdrawn": 0, "trials": [ { "nct": "NCT05408845", "title": "Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05965479", "title": "Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06145308", "title": "Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing", "status": "RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639219", "title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480384", "title": "Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB EMTANSINE": { "n": 6, "n_observational": 0, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT04620187", "title": "Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05408845", "title": "Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02318901", "title": "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer", "status": "TERMINATED", "last_update": "2019-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081609", "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TUCATINIB": { "n": 4, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT06828588", "title": "Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579380", "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07768358", "title": "Tucatinib Continuation Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ] }, "VANDETANIB": { "n": 14, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00098345", "title": "Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer", "status": "COMPLETED", "last_update": "2018-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00358956", "title": "A Study To Assess ZD6474 (ZACTIMA\u2122) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer", "status": "COMPLETED", "last_update": "2017-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410761", "title": "An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer", "status": "COMPLETED", "last_update": "2025-09-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00450138", "title": "Open Label, Phase I ZD6474 Head and Neck Cancer Study", "status": "COMPLETED", "last_update": "2016-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00459043", "title": "Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck", "status": "COMPLETED", "last_update": "2013-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00537095", "title": "Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer", "status": "COMPLETED", "last_update": "2024-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00720083", "title": "Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer", "status": "TERMINATED", "last_update": "2015-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00732745", "title": "Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction", "status": "TERMINATED", "last_update": "2011-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00923247", "title": "A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)", "status": "TERMINATED", "last_update": "2018-11-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00937417", "title": "S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2017-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01183559", "title": "A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery", "status": "COMPLETED", "last_update": "2021-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01414426", "title": "Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions", "status": "COMPLETED", "last_update": "2021-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01496313", "title": "To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer", "status": "COMPLETED", "last_update": "2025-10-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03630120", "title": "Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer", "status": "TERMINATED", "last_update": "2021-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZALUTUMUMAB": { "n": 7, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00093041", "title": "Zalutumumab in Head and Neck Cancer", "status": "COMPLETED", "last_update": "2023-06-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00382031", "title": "Zalutumumab in Patients With Non-curable Head and Neck Cancer", "status": "COMPLETED", "last_update": "2013-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00401401", "title": "Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer", "status": "TERMINATED", "last_update": "2011-12-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00496652", "title": "DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC", "status": "COMPLETED", "last_update": "2016-11-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00542308", "title": "Zalutumumab in Non-curable Patients With SCCHN", "status": "COMPLETED", "last_update": "2023-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00707655", "title": "Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01054625", "title": "Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "status": "COMPLETED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZANIDATAMAB": { "n": 5, "n_observational": 1, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07192068", "title": "Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152147", "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07631871", "title": "An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZENOCUTUZUMAB": { "n": 0, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "ZIMBERELIMAB": { "n": 16, "n_observational": 0, "n_active": 9, "n_withdrawn": 1, "trials": [ { "nct": "NCT05872724", "title": "Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)", "status": "RECRUITING", "last_update": "2023-05-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06055738", "title": "Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC", "status": "RECRUITING", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06155396", "title": "A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer", "status": "RECRUITING", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07424664", "title": "A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03629756", "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-05-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03972722", "title": "Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer", "status": "UNKNOWN", "last_update": "2019-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04772989", "title": "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies", "status": "COMPLETED", "last_update": "2025-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04854499", "title": "Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma", "status": "TERMINATED", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892875", "title": "A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers", "status": "WITHDRAWN", "last_update": "2023-11-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05437692", "title": "Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer", "status": "UNKNOWN", "last_update": "2022-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05798819", "title": "A Study of GLS-010 Plus Platinum-containing Chemotherapy\u00b1Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-04-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05824468", "title": "Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05891171", "title": "Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06107114", "title": "Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2023-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06128460", "title": "Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2023-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06727565", "title": "Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] } } } }